

ANGLO MEDICAL SCHEME

ANNUAL REPORT

FOR THE YEAR ENDED

31 DECEMBER 2020

ANNUAL REPORT

for the year ended 31 December 2020

ANGLO MEDICAL SCHEME

(Registration no. 1012)

The reports and statements set out below comprise the annual financial statements:

	Page
Scheme Details	
Report of the Board of Trustees	1 - 24
Statement of Responsibility by the Board of Trustees	25
Statement of Corporate Governance by the Board of Trustees	26
Independent Auditor's Report	27 - 29
Statement of Financial Position	30
Statement of Comprehensive Income	31
Statement of Changes in Funds and Reserves	32
Statement of Cash Flows	33
Notes to the Annual Financial Statements	34 - 80

SCHEME DETAILS

for the year ended 31 December 2020

(Registration no. 1012)

BOARD OF TRUSTEES

Elliott CC (Chairman)	Member Elected
McCallum DR (Vice-Chairman)	Member Elected
Abramowitz DE	Member Elected
Ameer KN	Employer Appointed (A)
Coetzer JP	Employer Appointed
Farrell MR	Member Elected (A)
Fox Dr FH	Member Elected
Hosking S	Member Elected (A)
Liston JB	Employer Appointed
Mamabolo NM	Employer Appointed
Mason-Gordon NJ	Member Elected
Matemera TS	Employer Appointed (A)
Mhlongo PQ	Member Elected
Moodley R	Employer Appointed
Ragolane NS	Member Elected (A)
Thompson HM	Employer Appointed
van der Bijl BD	Employer Appointed
van Vugt TD	Employer Appointed (A)

(A) Alternate trustee

PRINCIPAL OFFICER	Mrs FK Robertson
REGISTERED OFFICE	45 Main Street Johannesburg 2001
POSTAL ADDRESS	PO Box 62524 Marshalltown 2107
AUDITOR Registered address	PricewaterhouseCoopers Inc. 4 Lisbon Lane Waterfall City Jukskei View 2090
ADMINISTRATOR Registered address	Discovery Health (Pty) Ltd 1 Discovery Place Sandton 2146

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

The Board of Trustees hereby presents its report for the year ended 31 December 2020.

1. DESCRIPTION OF THE MEDICAL SCHEME

1.1. Terms of registration

The Anglo Medical Scheme (the Scheme) is a not for profit restricted medical scheme registered in terms of the Medical Schemes Act 131 of 1998 (the Act), Registration number 1012. The Scheme was established by Anglo American South Africa and its purpose is to provide medical cover to the employees, retirees and continuation members of the participating employer groups and their affiliated companies. The principal participating employer groups are Anglo Corporate Services South Africa (Pty) Limited, Mondi South Africa (Pty) Limited and Mpact Limited.

At 31 December 2020 the Scheme provided benefits to 8 713 members and 9 127 dependants. 51.11% of the members and dependants are female. Members are located primarily in Gauteng (39%), KwaZulu-Natal (35%) and the Western Cape (12%). The balance of membership is spread across South Africa.

1.2. Benefit options with Anglo Medical Scheme

Anglo Medical Scheme provides its members with a choice of three Plans; at 31 December 2020, Managed Care Plan serving 6 992 beneficiaries, average age 57.97 years, Standard Care Plan, 8 923 beneficiaries, average age 34.66 years and Value Care Plan 1 925 beneficiaries, average age 25.33 years old.

- **The Managed Care Plan (MCP)**

This is a comprehensive plan that offers unlimited cover for hospitalisation paid at 100% of the Scheme Reimbursement Rate and an additional top-up benefit which pays up to 230% of the Scheme Reimbursement Rate for specialist services rendered in hospital. Radiology and Pathology are unlimited and funded by the Scheme, but up to 100% of the Scheme Reimbursement Rate. Medical and surgical appliances, wheelchairs, hearing aids, chronic non-PMB medication and frail care are funded by the Scheme, subject to family and individual limits. Discretionary spend for out of hospital services are covered by the members' Medical Savings Accounts (MSA). Out of hospital specialist consultations and procedures are reimbursed up to 125% of the Scheme Reimbursement Rate.

- **The Standard Care Plan (SCP)**

This is a traditional medical plan with defined benefits and out of hospital family limits. Out of hospital benefits are limited and grouped by service under individual limits reimbursed at 100% of the Scheme Reimbursement Rate. Hospital cover is unlimited and paid at 100% of the Scheme Reimbursement Rate, subject to the network facilities.

- **The Value Care Plan (VCP)**

This is a primary health care plan providing services through a capitated arrangement with Kaelo Prime Cure (Pty) Ltd. Members may only obtain services from Kaelo Prime Cure facilities or network providers. Benefits are managed through limits, pre-authorisation and the application of Kaelo Prime Cure managed care protocols.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

1. DESCRIPTION OF THE MEDICAL SCHEME (continued)

1.3. Registered office

45 Main Street	PO Box 62524
Johannesburg	Marshalltown
2001	2107

1.4. Scheme administrator in office during the year under review

Discovery Health (Pty) Ltd
1 Discovery Place
Sandton
2146

1.5. Investment managers and custodian bank in office during the year under review

Allan Gray South Africa (Pty) Ltd
1 Silo Square, V&A Waterfront
Cape Town
8001

Coronation Asset Management (Pty) Ltd
Mont Clare Place, 7th Floor, Cnr Campground and Main Roads
Claremont
7700

Ninety One SA (Pty) Ltd
36 Hans Strydom Avenue, Foreshore
Cape Town
8001

Abax Investments (Pty) Ltd
The Oval, 1 Oakdale Road
Newlands
7700

1.6. Investment advisor in office during the year under review

Willis Towers Watson
1st Floor, Illovo Edge, 1 Harries Road
Illovo
Johannesburg
2196

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

1. DESCRIPTION OF THE MEDICAL SCHEME (continued)

1.7. Actuarial advisors in office during the year under review (continued)

NMG Consultants and Actuaries (Pty) Ltd
NMG House, 411 Main Avenue
Randburg
2125

Discovery Health (Pty) Ltd
1 Discovery Place
Sandton
2146

1.8. External auditor for the year under review, as approved by the Annual General Meeting

PricewaterhouseCoopers Inc.
4 Lisbon Lane
Waterfall City
Jukskei View
2090

2. SCOPE OF THE REPORT

2.1. Guidelines

The Anglo Medical Scheme adheres to the governance framework set out in the King Report.

The Scheme's financial policies and Annual Financial Statements comply with International Financial Reporting Standards (IFRS) as informed by the Medical Schemes Accounting Guide issued by the South African Institute of Chartered Accountants (SAICA) and the regulatory requirements as set out in the Act and its supporting Regulations.

2.2. Assurance

The Scheme's Actuaries comply with the best practice guideline issued in the Professional Guidance Note published by the Actuarial Society of South Africa.

The External Auditor expresses an audit opinion on whether the financial statements are, in all material respects, prepared in accordance with IFRS and the requirements of the Medical Schemes Act of South Africa. The External Auditor complies with International Standards on Auditing (ISA) in conducting the audit.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

2. SCOPE OF THE REPORT (continued)

2.3. Independence

The External Auditor has adopted independence standards in compliance with the requirement of the International Federation of Accountants, Code of Ethics (IFAC).

3. CORPORATE RESPONSIBILITY AND SUSTAINABILITY

Anglo Medical Scheme offers comprehensive healthcare benefits and services to its members which are quality, market competitive, cost-effective and consumer focused. These are supported by sound financial and risk management, administrative efficiency and the active participation of the members and employers. This ensures the Scheme's active compliance with the spirit of the law, ethical standards and international norms.

The affairs of the Scheme are managed by the Board of Trustees in compliance with the Scheme Rules in a manner that is fair, transparent, non-discriminatory and upholds the rights, values and dignity of members and other stakeholders. The Board performs its duties in accordance with the Board Charter and the Code of Conduct against which the Trustees bi-annually evaluate their performance and the performance of the Board as a whole. The Board shall at all times avoid conflicts of interests and Trustees are required to declare any interest they may have in any particular matter coming before the Board.

The Board has delegated some of its responsibilities to the duly appointed and constituted Committees (the Committees). It determines the Terms of Reference of the Committees, approves all policies proposed by the Committees and receives quarterly reports from the Committees. The Committees do not relieve the Trustees of any of their responsibilities, but assist them to fulfil those responsibilities.

The Audit Committee meets independently with the Administrator's Internal and Scheme's External Auditors regularly. Based on the review of the internal controls and risk management, the assurance and results of the audit and the recommendation of the Audit Committee, the Board of Trustees is of the opinion that the accounting policies, the internal control systems and the financial reporting practices are adequate and effective and that the basis for the preparation of the financial statements is sound.

The Scheme has supported aspects of the participating employers' social responsibility initiatives by adopting a progressive stand in the fight against HIV/AIDS and diseases such as diabetes and cancer. The Scheme regularly communicates with the membership on health and benefit matters in the recognition that a healthy, educated workforce becomes a sustainable asset to a participating employer.

The commitment to the long-term sustainability of the Scheme and its members remains the guiding principle of the Scheme. This has been strongly supported by the employers participating in the Scheme. To this end, the liability of the Scheme's significantly higher than industry average membership age has been pre-funded to ensure the Scheme's sustainability and the premiums and benefits remain market-related and competitive.

At the outset, the Covid-19 pandemic caused large-scale uncertainty worldwide, increasing both country and business risk in an unprecedented manner. The long term effects of the Covid-19 pandemic have yet to be fully quantified. Should these effects increase members' healthcare needs, result in loss of membership and / or continue to negatively impact financial markets over a sustained period, they could potentially pose a significant risk to the Scheme's Long Term Funding Strategy.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

3. CORPORATE RESPONSIBILITY AND SUSTAINABILITY (continued)

As it happens, there was a R14 million increase in comprehensive income for the year when compared to that seen in 2019. Significantly, healthcare expenditure was down by R86 million largely due to the lockdown and consequent delay in elective procedures while investment income was lower by R125 million.

The actuarial assessment of the Scheme's projected liability, when matched against the reserving level, showed a 2% decrease in the long term funding ratio from 104.5% to 102.9%, giving the Board of Trustees comfort that the Scheme Strategy withstood the immediate 2020 Covid-19 risk. It is not anticipated that any significant changes will be required in 2021. The Scheme will remain vigilant in monitoring and reviewing the progression of the pandemic and its long term consequences on the Scheme.

4. SCHEME STRATEGY

To achieve the vision of offering quality, cost effective and competitive benefits to meet the lifelong healthcare needs of the members, the Scheme has adopted several strategies as set out below.

4.1. Long term funding

The Council for Medical Schemes' (CMS) definition of a pensioner is a beneficiary over the age of 65. The Scheme's significantly higher beneficiary pensioner ratio than the industry average (26.2% compared to 8.6% - CMS report December 2020) increases the expected overall cost of providing adequate healthcare benefits to our members.

The Scheme previously entered into an arrangement with the participating employer groups and received grants to meet the ongoing and the future cost of providing benefits for the higher than usual proportion of pensioner members. Annual actuarial valuations are performed in order to calculate the funding needed to continue to provide market related benefits to all members. In 2015 the Board of Trustees revised the strategy ensuring long term funding (LTF) for a thirty-year period by when the pensioner ratio is expected to have normalised and be more in line with the market. With the advent of the Corona virus in 2020, the LTF will be reviewed thoroughly once the healthcare needs of members and the relevant healthcare expenditure cycles normalise and the full impact of the pandemic can be assessed.

In performing the actuarial valuation, the Scheme's actuaries make long-term assumptions which may differ from those used during the Scheme's annual short-term budget process, as disclosed elsewhere in the notes to the annual financial statements.

The calculated value of the Scheme's long term funding assets as at 31 December 2020 was R2.888 billion (2019 - R2.783 billion). This compares to the gross long-term liability calculated by the Scheme's consultants and actuaries of R2.806 billion (2019 - R2.663 billion), for the period to 2045.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

4. SCHEME STRATEGY (continued)

4.2. Investment strategy

The Scheme's investment strategy has been, and remains, aimed at maximising the annual return at an acceptable level of risk within the constraints of the Act. The Scheme believes that this risk should be managed, in part, by holding a conservative, yet diversified portfolio with a significant proportion of the assets providing returns that offer protection against inflation over the longer term.

The investment objective is to earn a return, net of fees, which exceeds the Consumer Price Index by at least 3.5% p.a. over a rolling five year period.

Period	Portfolio Performance	Consumer Price Index	CPI plus 3,5% p.a.
1 January to 31 December 2020 (p.a.)	2.5%	3.2%	6.7%
5 Years (p.a.)	4.6%	4.6%	8.1%
20 Years (p.a.) (since inception)	10.5%	5.4%	8.9%

As evidenced by the table above, the investment objective has not been achieved in the recent past, but has been achieved over the long term.

The Investment Committee thoroughly scrutinised the strategy, incumbent investment advisors and the asset managers during the period under review and concluded that, within the confines of the current Regulations, it was unlikely that a significantly different outcome could have been achieved if any one of the three parties had been changed. The Scheme diversified its portfolio by adding a fourth investment manager, Abax Investments (Pty) Ltd. The performance of the assets in 2020 and the ongoing market volatility have received considerable attention, including obtaining exemption from the Council for Medical Schemes to invest in global equities. The Trustees remain confident that the overall long term strategy will provide for the healthcare needs of the Scheme members into the foreseeable future.

4.3. Rate of contribution increase strategy

Due to the average age of the Scheme membership being significantly higher than the average age of the industry, healthcare costs are also significantly higher. Likewise, contributions and annual increases would need to be higher than the industry average to fund the payment of claims. To prevent members carrying the burden of these higher costs, an amount is budgeted annually, which is drawn from the long term funding reserve, to provide for the shortfall between the budgeted risk contribution income and claims incurred. In 2020 this amounted to R30 million (2019 - R135 million).

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

5. KEY PERFORMANCE MEASURES

- 5.1. To ensure the Scheme has sufficient reserves to cover the liability of the cost of providing for the healthcare need of members over their lifetime, the Scheme's actuaries annually determine the Scheme's liability which is matched against the level of reserving. The Accumulated Funds as at 31 December 2020 is R2.882 billion. The asset value projected for December 2020 is R2.888 billion.

The table below shows the funding ratio as at 31 December 2019 and the projected figure as at 31 December 2020 as per the actuarial valuation.

	2020 R'000	2019 R'000
Total long-term liabilities	2,806,100	2,662,700
Total value of assets	2,888,000	2,783,200
Current long-term funding ratio	102.9%	104.5%

- 5.2. Unlike most open schemes who measure their size, market share, annual growth, solvency levels etcetera, the Scheme closely monitors its value proposition to members and employers. The performance of the Scheme is measured by the contribution increase that is effected annually, coupled with benefit changes. The aim of the Scheme is to continue to maintain contribution increases close to the industry average and the generally accepted medical inflation rate of CPI plus 3%, as seen in the table below.

Year	2021	2020	2019	2018	2017
Average annual contribution increase per member	3.9%	9.5%	9.5%	8.9%	11.4%
CPI	3.2%	4.5%	4.1%	4.7%	5.3%
Industry gross average increase per beneficiary *	-	9.6%	9.3%	8.2%	11.3%

* The industry figure quoted serves as a guide only. It reflects the industry average percentage increase in the gross contribution income per beneficiary as reported by the Council for Medical Schemes.


- 5.3. The Scheme aims to provide members with better value for money than they would be able to purchase in the open market. The three Plans are independently evaluated against eight to ten similar competitor products annually to ensure this aim is met. The benefits provided in 2020 scored higher than average across all three Plans, and were all offered at lower than average contribution rates, indicating better value for money than could be purchased in the market.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

5. KEY PERFORMANCE MEASURES

- 5.4. 2020 saw the Scheme's administrator, Discovery Health, deliver above average service on almost all the contracted service level metrics, thus meeting the service excellence promise to members. The graph below depicts the various single service measures applicable.




SL: Service Level

MBR: Member Based Research measures member happiness

FCR: First Call Resolution measures percentage of calls resolved on first contact

TWT: Today's work today

The graph below measures the average number of days between a claim being received and paid.



- 5.5. The Council for Medical Schemes requires that non-healthcare costs are kept below 10% of gross contribution income. The 2020 non-healthcare cost compared well against previous years and is well below the Council's requirements.

Year	2020	2019	2018	2017	2016
Non-healthcare costs as a percentage of gross contribution income	5.7%	5.7%	6.2%	5.9%	6.2%
Industry average*	-	5.5%	5.7%	6.0%	6.3%

* Industry average percentage for restricted membership medical schemes as reported by the Council for Medical Schemes.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

6. REVIEW OF THE ACCOUNTING PERIOD'S ACTIVITIES

6.1. Operational results

The Scheme budgets a small surplus each year after taking into consideration the investment income and the draw down from the reserves required to cover the expected contribution shortfall.

	2020 R'000	2019 R'000
Net healthcare result	(10,838)	(138,057)
Managed Care Plan	(38,516)	(121,231)
Standard Care Plan	26,666	(17,098)
Value Care Plan	1,012	272
Add: Net investment and other income	70,128	183,242
Net surplus for the year	59,290	45,185

The adult and child contributions are rebalanced annually by Plan, adjusting for changes in family size and ageing trends. Cognisance is taken of the employee salary increases and the claims experience of each Plan when determining contribution increases. For the period under review, the increases and contributions were as follows:

	2020 R		2019 R	
Average contribution increase 9.5%	Adult	Child	Adult	Child
Managed Care Plan	4,945	1,145	4,515	1,045
Standard Care Plan	2,705	815	2,470	745
Value Care Plan	975	240	895	220

6.2. Outstanding risk claims

Movements in the outstanding risk claims provision are set out in Note 5 to the financial statements. The basis of calculation is consistent with the prior year.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

6. REVIEW OF THE ACCOUNTING PERIOD'S ACTIVITIES (continued)

6.3. Accumulated funds

Movements in the accumulated funds are set out in the Statement of Changes in Accumulated Funds as reflected on page 32 of this document.

	2020 R'000	2019 R'000
Total members' funds per Statement of Financial Position	2,882,468	2,823,178
Less: Cumulative unrealised net gain on measurement of investments to fair value	(211,852)	(202,566)
Accumulated funds per Regulation 29 of the Act	2,670,616	2,620,612
Gross contribution income (Note 8)	593,438	562,827
Accumulated funds ratio per Regulation 29 (including unrealised gains)	485.7%	501.6%
Accumulated funds ratio per Regulation 29 (excluding unrealised gains)	450.0%	465.6%
Minimum ratio required by Regulation 29 of the Act	25.0%	25.0%

Refer to Note 4.1 of the Board of Trustees' report for the reasons for this level of funding.

The average accumulated funds per member as at 31 December 2020 was R330,824 (2019: R318 679).

6.4. Medical Savings Accounts

Refer to Note 1.7 and Note 6 of the financial statements.

The liability to members in respect of the Medical Savings Accounts is reflected as a liability in the annual financial statements, repayable in terms of Regulation 10 of the Act.

REPORT OF THE BOARD OF TRUSTEES
for the year ended 31 December 2020

6.5. OPERATIONAL STATISTICS

The detailed statistics per plan are reflected in the table below:

	Managed Care Plan			Standard Care Plan			Value Care Plan			Total		
	2020	2019	%	2020	2019	%	2020	2019	%	2020	2019	%
Number of members at end of accounting period	3,980	4,192	-5%	3,862	3,849	0%	871	818	6%	8,713	8,859	-2%
Average (avg) number of members for the period	4,071	4,261	-4%	3,870	3,856	0%	848	797	6%	8,789	8,914	-1%
Beneficiaries at end of accounting period	6,992	7,502	-7%	8,923	8,893	0%	1,925	1,773	9%	17,840	18,168	-2%
Average (avg) number of beneficiaries for the period	7,179	7,632	-6%	8,897	8,934	0%	1,862	1,740	7%	17,938	18,306	-2%
Beneficiaries per member at end of accounting period	1.76	1.79	-2%	2.31	2.31	0%	2.21	2.17	2%	2.05	2.05	0%
Avg age of beneficiaries	57.97	57.11	2%	34.66	34.53	0%	25.33	25.33	0%	42.79	42.94	0%
Pensioner ratio (beneficiary > 65 years)	51.30%	49.61%	3%	11.89%	11.84%	0%	1.71%	1.71%	0%	26.24%	26.44%	-1%
Avg gross contribution per member per month (R)	7,479	6,927	8%	4,590	4,232	8%	1,465	1,343	9%	5,627	5,262	7%
Avg gross contribution per beneficiary per month (R)	4,241	3,867	10%	1,996	1,826	9%	667	615	8%	2,757	2,562	8%
Avg gross claim per member per month (R)	7,642	8,618	-11%	3,668	4,276	-14%	1,296	1,251	4%	5,280	6,081	-13%
Avg gross claim per beneficiary per month (R)	4,333	4,811	-10%	1,596	1,846	-14%	590	573	3%	2,587	2,961	-13%
Avg administration cost per member per month (R)	344	327	5%	344	327	5%	67	65	3%	317	304	5%
Avg administration cost per beneficiary per month (R)	195	183	7%	150	141	6%	30	30	3%	155	148	5%
Relevant healthcare expenses as a % of risk contributions	107.5%	139.3%	-23%	79.9%	101.0%	-21%	88.5%	93.2%	-5%	95.6%	122.3%	-22%
Administration cost as a % of gross contributions	4.6%	4.7%	-3%	7.5%	7.7%	-3%	4.6%	4.8%	-5%	5.6%	5.8%	-2%

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

7. RISK

The Board of Trustees is responsible for the total risk management of the Scheme and has determined the risk strategy and policies based on the Scheme's appetite or tolerance for risk in line with the governance framework as set out in the King Report.

The Scheme has implemented a robust risk management framework, which ensures an effective ongoing process of evaluation of both the potential and current risks on a long-term and a daily basis. Assessments are completed enabling the Scheme and management of the administrator to proactively identify, assess, monitor and manage the risks to which the Scheme is exposed.

The Internal Control risk assessment process provides a structured methodology to identify the key risks within each area of business and assess the controls upon which management relies to mitigate these risks.

The Board of Trustees identified the primary risks facing the Scheme to be as follows:

7.1. Strategic risk

The potential loss of value to the members and employer groups due to the Scheme's inability to provide competitive, cost-effective, quality products and services that are market related to meet employer and member needs.

It is expected that the short to medium term pandemic risk impact on the healthcare costs and the investment returns will work through the system without the need to change strategic direction.

Factors driving this risk relate to the Scheme's inability to remain competitive due to financial pressures such as the investments not delivering the required returns and escalation of healthcare costs. Much of this risk management and mitigation is discussed under Strategy, point 4 and under Committees of the Board of Trustees, point 11.

The risk of a long term funding strategy is that legislative changes might impact the Scheme's ability to provide for the lifelong healthcare needs of the members. The proposed National Health Insurance policy and the amendments to the Medical Schemes Act may have a profound impact on the way the Scheme operates.

7.2. Operational risks

The risk of loss arising from failed or inadequate internal processes, people, systems and/or external events. This category includes legal risk, project risk, business continuity risk, data risk, information technology risk, and human capital risk. The day-to-day management of the Scheme in accordance with all legislative requirements and best practice guidelines is monitored and measured on an ongoing basis and is discussed under point 8.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

7. RISK (continued)

7.3. Investment risk

The Scheme has identified investment risk as the risk of a decline in the net realisable value of investment assets as a result of adverse movements in market prices or factors specific to an investment itself which may impact on the Scheme's long term objectives. These may arise due to movements in interest rates, exchange rates, or equity and commodity prices and may be a result of macro global trends, pandemics or internal domestic fluctuations.

7.4. Compliance risk

As defined in the Act, the business of a scheme is to undertake liability in return for a premium or contribution and to grant assistance in defraying expenditure incurred in obtaining any relevant health service. Compliance risk is the risk of statutory or regulatory sanction or material financial losses as a result of a failure to comply with applicable laws, regulations or supervisory requirements.

8. RISK MANAGEMENT AND MITIGATION

Refer to Notes 24 and 25 of the annual financial statements.

The Scheme maintains a sound system of risk management and internal control providing reasonable assurance in the achievement of the organisational objectives with respect to:

- Effectiveness and efficiency of operations;
- Safeguarding of the Scheme's assets (including information);
- Compliance with applicable laws, regulations and supervisory requirements;
- Supporting business sustainability under normal and adverse operating conditions;
- Reliability of reporting; and
- Behaving responsibly towards all stakeholders.

The risk assessment process:

- Focuses on the underlying causes of risks and not just the financial impacts;
- Assesses existing controls;
- Identifies priority areas so that effective testing of controls can take place;
- Assists management to determine the actions required to address the key risks identified;
- Assists in forecasting the Scheme's potential risk exposure in the future; and
- Allocates actions to staff that are able to effectively oversee the required activities.

The Board ensures that a systematic and documented assessment of the processes and outcomes surrounding key risks is undertaken annually and at appropriately considered intervals for the purpose of making its public statement on risk management.

Risk management and internal control are practiced throughout the Scheme, and are embedded in day-to-day activities.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

8. RISK MANAGEMENT AND MITIGATION (continued)

Several methods are employed to assess and monitor risk exposure for individual types of risks insured and overall risks. These methods include the use of internal risk measurement models, sensitivity analyses and scenario analyses all of which are subject to strict audit criteria.

In addition to the Scheme's other compliance and enforcement activities, the Board has implemented a confidential reporting process ("whistleblowing").

The Board has delegated the risk management process to the Management Committee and the oversight of the risk management to the Audit Committee and Investment Committee. These Committees are answerable to the Board and do not relieve the Trustees of any of their responsibilities, but assists them to fulfil those responsibilities.

8.1. Risk transfer arrangements

Refer to Note 10 of the financial statements.

In line with the vision to soundly manage the claims risk, the Scheme has entered into risk-sharing agreements with third party service providers to ensure cost effective services. This provides the Scheme with the ability to mitigate an identified risk by agreement with a third party service provider. The principle is based on the sharing of predefined potential claims loss in return for exclusivity of delivering the service.

The following risk transfer capitation arrangements were in place for the year:

Organisation	Services capitated	Plan
Kaelo Prime Cure (Pty) Ltd	Provides primary healthcare services at Healthcare centres and contracted network service providers, including a limited hospital benefit.	Value Care Plan
Netcare 911 (Pty) Ltd	Provides emergency transport services and other ambulance services.	Managed Care Plan Standard Care Plan
Centre for Diabetes and Endocrinology (CDE)	Provides diabetes related medical services including related hospitalisation expenses.	Managed Care Plan Standard Care Plan
Dental Risk Company	Provides dental related medical services.	Standard Care Plan

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

9. GOVERNANCE

The Scheme vision is supported by the Board Charter wherein the Board commits to act in good faith with utmost due care, diligence and skill. Each Trustee is required to aspire to the core ethical principles of fairness, transparency, honesty, non-discrimination, accountability and respect for human dignity and rights.

The Board delegates the duty of delivery and operation of the functions to the duly constituted Committees while remaining fully responsible for the performance of the Scheme and accountable to the membership. The principles of good governance and sound business ethics are firmly adhered to through the adoption of the King guidelines, a culture of rigorous risk and financial management and a stringent auditing process.

The Scheme complies with International Financial Reporting Standards and all the relevant legislative requirements.

10. MANAGEMENT

10.1. Board of Trustees in office during 2020:

Elliott CC (Chairman)	Member Elected
McCallum DR (Vice-Chairman)	Member Elected
Abramowitz DE	Member Elected
Ameer KN	Employer Appointed (A)
Coetzer JP	Employer Appointed
Farrell MR	Member Elected (A)
Fox Dr FH	Member Elected
Hosking S	Member Elected (A)
Liston JB	Employer Appointed
Mamabolo NM	Employer Appointed
Mason-Gordon NJ	Member Elected
Matemera TS	Employer Appointed (A)
Mhlongo PQ	Member Elected
Moodley R	Employer Appointed
Ragolane NS	Member Elected (A)
Thompson HM	Employer Appointed
van der Bijl BD	Employer Appointed
van Vugt TD	Employer Appointed (A)

(A) Alternate trustee

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

10. MANAGEMENT (continued)

10.2. Management Committee in office during the year under review:

McCallum DR (Chairman); Coetzer JP; Elliott CC; Fox FH; Liston JB; Mhlongo PQ; van der Bijl BD.

10.3. Audit Committee in office during the year under review:

Prinsloo J (Chairman, Independent); Kapp G (Independent); McCallum DR; Moodley R; van Zyl C (Independent).

10.4. Ex Gratia Committee in office during the year under review:

Fox Dr FH (Chairman); Farrell MR; Mamebolo NM; Mhlongo PW; Pienaar J (Independent).

10.5. Investment Committee in office during the year under review:

Mason-Gordon NJ (Chairman); Abramowitz DE; Clark B (Independent); Liston JB; Mamabolo NM; Thompson HM

10.6. Disputes Committee in office during the year under review:

Badenhorst C (Member elected); M Bhikoo (Independent); PA Laubscher (Member elected); Payne N (Member elected);

10.7. Principal Officer and staff in office during the year under review:

Robertson FK	Principal Officer	Scheme employed
Gröpp-Els E	Scheme and Clinical Manager	Scheme employed
Friese J	Communications Manager	Scheme employed
Landsberg Y	Scheme Secretary	Scheme employed

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

11. COMMITTEES OF THE BOARD OF TRUSTEES

11.1. Audit Committee

The Audit Committee (the Committee) is established in accordance with the provisions of the Act and is mandated by the Board of Trustees by written terms of reference as to its membership, authority and duties. The Committee consists of five members, two of whom are members of the Board of Trustees.

The majority of the Committee, including the chairperson, is independent and does not serve on the Board of the Scheme or act on behalf of the administrator.

In accordance with the provisions of the Act, the primary responsibility of the Committee is to assist the Board of Trustees in carrying out its duties relating to the Scheme's accounting policies, internal control systems and financial reporting practices.

The External Auditor formally reports to the Committee on critical findings arising from the statutory audit. The Administrator's Internal Auditor attends meetings and reports findings to the Committee.

The Committee met regularly during the year and both the Internal and External Auditor are invited to attend all Committee meetings and they also had unrestricted access to the Chairman of the Committee at all times.

The Committee is pleased to report that:

- It has carried out its duties in terms of the Act and the Board of Trustees written Committee Charter;
- The External Auditor has confirmed their independence;
- The assurances provided by Administrator management, the External Auditor and the Internal Auditor have satisfied the Committee that the controls are adequate and effective;
- It has ensured the co-ordination of the approaches of the Internal and External Auditor and has had oversight of the financial reporting process;
- It has evaluated the effectiveness of the risk management and governance;
- It has received the assurance from the External and Internal Auditors that nothing had come to their attention that compromised the effectiveness of the controls as they apply to the annual financial statements; and
- It has reviewed the approach taken to the application of King and has found no material weakness.

The Committee has reviewed the Scheme's annual financial statements, reviewed the accounting policies, obtained assurances from the External Auditor and recommended the adoption of the annual financial statements by the Board of Trustees for presentation to members.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

11. COMMITTEES OF THE BOARD OF TRUSTEES (continued)

11.2. Investment Committee

The Investment Committee (the Committee) is a duly constituted committee of the Board of Trustees and has the responsibility to assist the Board of Trustees in carrying out their duties relating to the Scheme's investment policy and strategy. It is mandated by means of written terms of reference as to its membership, authority and duties.

The Committee consists of six members, and includes an independent member. The Scheme appointed Willis Towers Watson as independent investment consultants to assist the Committee. The current investment managers of the Scheme are Ninety One SA (Pty) Ltd, Coronation Asset Management (Pty) Ltd, Allan Gray South Africa (Pty) Ltd and Abax Investments (Pty) Ltd, who was appointed in February 2020.

The Committee met regularly during the year and the investment consultant attended all Committee meetings with the investment managers, each attending at least one meeting per annum.

The Committee reviews the strategy regularly in accordance with the mandate set by the Board of Trustees and advises on the structure of the portfolio as well as risk mitigation to ensure sustainability of the Scheme's long-term liability funding requirements.

11.3. Management Committee

The Management Committee (the Committee) is mandated by the Board of Trustees to oversee and review the management of the day-to-day administrative and financial risk management (with the exception of investment risk management), and financial functions of the Scheme by means of written terms of reference as to its membership, authority and duties.

This Committee is chaired by the Vice Chairman of the Scheme and comprises seven Trustees who meet a minimum of four times a year to review key indicators and make formal proposals and recommendations to the Board of Trustees. The Chairman of the Scheme is invited to attend the meetings ex-officio.

Administrative risk management measures are employed to ensure good governance of the access to benefits; these include, but are not limited to pre-authorisation, case management, service provider profiling, billing audits and interventions in respect of fraud.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

11. COMMITTEES OF THE BOARD OF TRUSTEES (continued)

11.4. Ex Gratia Committee

The Ex Gratia Committee (the Committee) is mandated by the Board of Trustees to assist members by awarding ex gratia payments where services were either denied or rejected due to limited or uncovered benefits, as deemed appropriate according to the individual merits of each case. These awards are granted against an approved budget on the basis of financial hardship of the individual member and medical necessity where benefits are not provided for or expressly excluded from the rules of the Scheme.

This committee consists of 4 Trustees of which one is an alternate Trustee and also an independent member.

The Committee is governed by means of written terms of reference as to its membership, authority and duties. This Committee meets every two months.

11.5. Disputes Committee

The Disputes Committee (the Committee) is an independent Committee and comprises three members who are appointed by members at the Annual General Meeting. The appointed members may not be administrators, trustees or officers of the Scheme.

The main function of the Committee is to deal with member disputes where the member is dissatisfied with any decision taken by the Board or a Committee or the administrator of the Scheme.

11.6. Regional Committees

Regions are established based on the number of members represented in a specific region. Business units are defined and designated by participating employers in each region.

There are currently three regions, namely; Central Region (Gauteng, Limpopo and Mpumalanga), Eastern Region (KwaZulu Natal) and the Southern Region (Western Cape, Eastern Cape and Northern Cape).

Each Regional Committee comprises a chairperson, Trustee or Alternate Trustee, employer and member representative and meets at least annually. The main function of these Committees is to provide feedback from the Board of Trustees meetings to the participating employers of the Scheme; who in turn provide feedback to all their respective active and retired members.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

12. TRUSTEE AND NON-TRUSTEE MEMBERS ATTENDANCE AT COMMITTEE MEETINGS

	Board of Trustees		Audit Committee		Investment Committee		Management Committee		Ex-gratia Committee		Disputes Committee	
Trustees	A	B	A	B	A	B	A	B	A	B	A	B
Elliott CC	7	7					4	3				
McCallum DR	7	7	4	4			4	4	1	1		
Abramowitz DE	7	6			5	5						
Coetzer JP	7	7					4	4	1	1		
Fox Dr FH	7	7					4	4	5	5		
Liston J	7	6			5	5	4	4				
Mamabolo NM	7	7			5	4			5	4		
Mason-Gordon NJ	7	6			5	5						
Mhlongo PQ	7	6					4	4	5	5		
Moodley R	7	7	4	4								
Thompson HM	7	6			5	3						
van der Bijl BD	7	6					4	3				
Alternate Trustees and Consultants												
Ameer KN		*4										
Badenhorst C											1	1
Bhikoo M											1	1
Clark B					5	4						
Farrell MR		*4							5	5		
Hosking S												
Kapp G			4	4								
Laubscher PA											1	1
Matemera TS												
Payne N											1	1
Pienaar J									5	5		
Prinsloo J			4	4								
Ragolane NS		*4										
van Vugt TD		*1										
van Zyl C			4	4								

A = maximum possible attendance

B = actual attendance

* = voluntary attendance

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

13. ACTUARIAL SERVICES

The Scheme's actuaries are contracted to identify and monitor health related risks, establish claiming patterns and recommend contribution and benefit levels. They also participate in the monthly and annual calculations of the outstanding claims incurred, but not yet reported and paid by the Scheme (IBNR). The Scheme's long-term funding valuation is calculated and reviewed annually by the actuaries.

14. GUARANTEES RECEIVED BY THE SCHEME FROM A THIRD PARTY

None.

15. INVESTMENTS IN AND LOANS TO EMPLOYERS OF MEMBERS OF THE SCHEME AND TO OTHER RELATED PARTIES

Refer to related parties disclosure in Note 21 of the financial statements.

16. RELATED PARTY TRANSACTIONS

Refer to related parties disclosure in Note 21 of the financial statements. Trustee remuneration is disclosed in Note 22 of the annual financial statements.

17. SUBSEQUENT EVENTS

The Trustees confirm that no events have occurred subsequent to the end of the accounting period to the date of this report that affect the annual financial statements that should be brought to the attention of the members of the Scheme.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

18. NON-COMPLIANCE WITH THE MEDICAL SCHEMES ACT

The Trustees are of the opinion that there are no material deviations from the Act as a result of the Scheme having obtained the necessary exemptions from the Council for Medical Schemes to achieve compliance.

18.1. Outstanding contributions

Nature and impact

In terms of Section 26(7) of the Act, contributions should be received in accordance with the rules of the Scheme. Per the Scheme rules, contributions are required to be received within three days after their due date. Instances were noted where contributions were received late.

Causes for failure

Balances after three days are due to reconciling discrepancies between the participating employers and the Scheme. The risk of default on payments due to the Scheme is small because of the restricted nature of the Scheme and employer base. The Trustees consider this to be immaterial.

Corrective action

Suspension policies are in place and applied where contributions are outstanding for individual paying members outside the participating employers' obligation.

18.2. Investment in participating employer

Nature and impact

Section 35(8)(a) of the Act states that a medical scheme shall not invest any of its assets in a participating employer. During the year the Scheme had exposure to investments in participating employer groups through pooled investment vehicles.

Causes for failure

The Scheme invests in pooled investment vehicles which allow investment managers discretion to invest in a combination of shares and bonds that will best achieve their stipulated benchmark. Given this approach, the Scheme was exposed to participating employer shares.

Corrective action

The Scheme applies annually to the Council for Medical Schemes and received an exemption from this section of the Act. This exemption is valid until 30 November 2022.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

18. NON-COMPLIANCE WITH THE MEDICAL SCHEMES ACT (continued)

18.3. Investment in administrator

Nature and impact

Section 35(8)(c) of the Act states that a medical scheme shall not invest any of its assets in any administrator. During the year the Scheme had exposure to such investments through pooled investment vehicles.

Causes for failure

The Scheme invests in pooled investment vehicles which allow investment managers discretion to invest in a combination of shares and bonds that will best achieve their stipulated benchmark.

Corrective action

The Scheme applies annually to the Council for Medical Schemes and received an exemption from this section of the Act. This exemption is valid until 30 November 2022.

18.4. Sustainability of benefit options

Nature and impact

In terms of section 33(2) of the Act, each benefit option shall be self-supporting in terms of membership and financial performance. At 31 December 2020, the Managed Care plan incurred deficits before investment income as set out in Note 23 to the financial statements.

Causes for failure

The Board of Trustees annually maintain market related benefit offerings and competitive contribution increases. Due to the Scheme demographics, this gives rise to the non-compliance.

Corrective action

Anglo American South Africa sold numerous subsidiaries over a period of time resulting in the loss of active employees and retention of pensioners. To compensate the Scheme for the resultant high pensioner ratio and expected deterioration of the claiming profile, the participating employers pre-funded the additional liability to the extent that the Scheme could maintain market related benefits and contribution increases into the future. The Scheme meets its responsibility to the members by subsidising the expected claims excess over contributions from the reserves. The Trustees will continue to review the investment returns to align with the strategy ensuring sustainability.

The Council for Medical Schemes is aware of the Scheme's strategy and approves the benefits and contributions annually without any requirement to take further corrective action.

REPORT OF THE BOARD OF TRUSTEES

for the year ended 31 December 2020

18. NON-COMPLIANCE WITH THE MEDICAL SCHEMES ACT (continued)

18.5. Payment of claims within 30 days

Nature and impact

In terms of section 59(2) of the Act a member or provider claim should be settled within 30 days of submission. Instances were noted where settlements took more than 30 days.

Causes for failure

Delays can occur when accounts are referred for clinical audit or other investigations. These are however exceptions and claims are generally paid within the prescribed time.

Corrective action

The Scheme is aware of the requirements and complies as far as possible. It is however an inherent part of the industry that a limited number of problematic claims may exceed the payment requirement of 30 days.

18.6. Prescribed minimum benefits

Nature and impact

Section 29(1)(o) and Regulation 8 provide the scope and level of minimum benefits that the Scheme must provide to members and dependants.

Causes for failure

During the year under review there were isolated instances where the Scheme did not pay claims in accordance with the scope and level of minimum benefits.

Corrective action

The Scheme has aligned its interpretation of prescribed minimum benefits with CMS's interpretation, and affected claims are being reprocessed to ensure correct payment.

STATEMENT OF RESPONSIBILITY BY THE BOARD OF TRUSTEES

The Trustees are responsible for the preparation and fair presentation of the annual financial statements of the Anglo Medical Scheme (the Scheme), set out on pages 30 to 80, comprising the statement of financial position at 31 December 2020, the statement of comprehensive income, statement of changes in funds and reserves, statement of cash flows for the year then ended and the notes to the financial statements, which include a summary of significant accounting policies and other explanatory notes, in accordance with International Financial Reporting Standards (IFRS) and the requirements of the Medical Schemes Act of South Africa. In addition, the Trustees are responsible for preparing the report of the Board of Trustees.

The Trustees are also responsible for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and for maintaining adequate accounting records and an effective system of risk management.

The Trustees have reviewed the Scheme's budget for the year ending 31 December 2021. The Trustees have made an assessment of the Scheme's ability to continue as a going concern and have no reason to believe the business will not be a going concern in the year ahead.

On the basis of this review and in light of the current financial position and available resources, the Trustees have no reason to believe that the Scheme will not be a going concern for the foreseeable future.

The auditor is responsible for reporting on whether the financial statements are fairly presented in accordance with the applicable financial reporting framework.

Approval of the annual financial statements

The annual financial statements of Anglo Medical Scheme, as identified in the first paragraph, were approved and authorised for issue by the Trustees on 7 April 2021 and are signed on their behalf by:


Colleen Catherine Elliott
21/04/2021 16:00:41 (UTC+02:00)
Signed by Colleen Catherine Elliott,
colleen.elliott9@icloud.com


SIGNIFLOW.COM

Mrs CC Elliott
Chairman


Duncan MacCallum
21/04/2021 15:38:51 (UTC+02:00)
Signed by Duncan MacCallum,
duncan@drmconsulting.co.za

SIGNIFLOW.COM

Mr DR McCallum
Vice-Chairman


Fiona Robertson
21/04/2021 11:29:38 (UTC+02:00)
Signed by Fiona Robertson,
Fiona.Robertson@angloamerican.c

SIGNIFLOW.COM

Ms FK Robertson
Principal Officer

STATEMENT OF CORPORATE GOVERNANCE BY THE BOARD OF TRUSTEES

Anglo Medical Scheme (the Scheme) is committed to the principles and practice of responsibility, accountability, fairness and transparency in its dealings with all stakeholders and applies good governance principles.

The Scheme is committed to ensuring compliance within recognised frameworks and conducting its affairs based on ethical values, by the adoption of risk assessment, evaluation and management processes and regular monitoring of third party administrators and providers in accordance with contractual service level agreements. This includes evaluating the performance of the Board and the Board committees against agreed terms of reference and performance targets, the establishment and management of internal controls by assessing the adequacy and effectiveness through the reports of the internal auditor and calling on expert and professional advice when required.

BOARD OF TRUSTEES

The Board of Trustees and its committees meet regularly and monitor the performance of the Administrator and other service providers. They address a range of key issues and ensure discussion on items of policy, strategy and performance are informed and constructive.

All Trustees have access to the advice and services of the Principal Officer and, where appropriate, the Board may seek independent professional advice at the cost of the Scheme.

INTERNAL CONTROL

The Administrators of the Scheme maintain internal controls and systems designed to provide reasonable assurance of the integrity and reliability of the financial statements and to safeguard, verify and maintain accountability for its assets. Such controls are based on established policies and procedures and are implemented by trained personnel with the appropriate segregation of duties.

No event or item has come to the attention of the Board of Trustees that indicates any material breakdown in the functioning of the key internal controls and systems during the year under review.

Colleen Catherine Elliott

Colleen Catherine Elliott
21/04/2021 15:57:17 (UTC+02:00)
Signed by Colleen Catherine Elliott,
colleen.elliott9@icloud.com

SIGNIFLOW.COM

Duncan MacCallum

Duncan MacCallum
21/04/2021 15:39:23 (UTC+02:00)
Signed by Duncan MacCallum,
duncan@drmconsulting.co.za

SIGNIFLOW.COM

Fiona Robertson

Fiona Robertson
21/04/2021 11:29:53 (UTC+02:00)
Signed by Fiona Robertson,
Fiona.Robertson@angloamerican.c

SIGNIFLOW.COM

Mrs CC Elliott
Chairman

Mr DR McCallum
Vice-Chairman

Ms FK Robertson
Principal Officer

7 April 2021



Independent Auditor's Report

To the Members of Anglo Medical Scheme

Report on the financial statements

Opinion

We have audited the financial statements of Anglo Medical Scheme (the Scheme), set out on pages 30 to 80, which comprise the statement of financial position as at 31 December 2020, and the statement of comprehensive income, the statement of changes in funds and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, these financial statements present fairly, in all material respects, the financial position of the Scheme as at 31 December 2020, and its financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards and the requirements of the Medical Schemes Act of South Africa.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Scheme in accordance with the Independent Regulatory Board for Auditors' Code of Professional Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of financial statements in South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the corresponding sections of the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards).

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter	How our audit addressed the key audit matter
Outstanding risk claims provision The outstanding risk claims provision of R23,074,000 at year-end as described in Note 5 to the financial statements, is a provision recognised for the estimated cost of healthcare benefits that have been incurred prior to year-end but that were only reported to the Scheme after year-end. The outstanding claims provision is calculated by the Scheme's actuaries which is reviewed by management and the Audit Committee and recommended to the Board of Trustees for approval. The Scheme's actuaries use an actuarial model, based on the Scheme's actual claim development patterns throughout the year, to project the year-end provision. This model applies the Basic Chain Ladder ("BCL") method. The claim service date, processing date and amount are used to derive claim development patterns. These historical patterns are then used to estimate the outstanding claims provision.	 We obtained an understanding from the Scheme's actuaries regarding the process to calculate the outstanding risk claims provision, which included the design and implementation of controls within the process. The actuarial model applied by the Scheme is one that is generally applied within the medical scheme industry. We obtained the actual claims data from the member administration system covering the year ended 31 December 2020. The actual claims data includes the impact of COVID-19 and therefore the impact has been taken into account in the claims patterns in the outstanding claims provision. For a sample of actual claims received by the Scheme in the 31 December 2020 financial year, we tested the accuracy of the service and process dates. No material inconsistencies were noted.

PricewaterhouseCoopers Inc., 4 Lisbon Lane, Waterfall City, Jukskei View 2090
Private Bag X36, Sunninghill 2157, South Africa
T: +27 (0) 11 797 4000, F: +27 (0) 11 209 5800, www.pwc.co.za

Chief Executive Officer: L S Machaba
The Company's principal place of business is at 4 Lisbon Lane, Waterfall City, Jukskei View, where a list of directors' names is available for inspection.
Reg. no. 1998/012055/21, VAT reg.no. 4950174682.

<p>We identified this to be a matter of most significance to the audit because of the uncertainty in the projected claims pattern. A change in the projected claims pattern can cause a material change to the amount of the provision.</p>	<p>We substantively tested a sample of claims against the relevant Scheme rules and assessed completeness of the claims data.</p> <p>The claims data that was included in the Scheme’s actuarial model was agreed to the above actual claims data with no material inconsistencies noted.</p> <p>To assess the reasonableness of the Scheme <i>actuaries’</i> estimation process, we compared the actual claim results in the current year to the prior year provision. Based on our assessment, the estimation process was considered reasonable.</p> <p>We have evaluated management’s experts by assessing their competence, capability, and objectivity and noted no aspects requiring further consideration. We also obtained the outstanding claims provision report from the Scheme’s actuaries and assessed whether the inputs, assumptions, methodology and findings per the report were consistent with our testing above. Based on the results of our assessment we accepted the inputs, assumptions, methodology and findings as reasonable.</p> <p>We obtained the actual claims run-off report up to 31 March 2021 from the Scheme’s management. For a sample of claims from the report, we tested the occurrence and accuracy of the claims as well as the accuracy of the related service dates and we identified no material inconsistencies.</p> <p>We enquired from the Scheme’s management whether there were delays in processing claims at year-end that could possibly impact the claims run-off pattern subsequent to year-end. Management confirmed that there were no such delays.</p> <p>We obtained the treatment pre-authorisations approved prior to year-end from the administrator and selected a sample to assess if any of the selected claims related to a health insurance event before year end were included in the actual claims run-off report up to 31 March 2021. No material inconsistencies were noted.</p>
---	---

Other Information

The Scheme’s trustees are responsible for the other information. The other information comprises the information included in the document titled “*Anglo Medical Scheme Annual Report for the year ended 31 December 2020*”. The other information does not include the financial statements and our auditor’s report thereon.

Our opinion on the financial statements does not cover the other information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Scheme’s Trustees for the Financial Statements

The Scheme’s trustees are responsible for the preparation and fair presentation of the financial statements, in accordance with International Financial Reporting Standards and the requirements of the Medical Schemes Act of South Africa, and for such internal control as the Scheme’s trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Scheme’s trustees are responsible for assessing the Scheme’s ability to continue as a

going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the Scheme's trustees either intend to liquidate the Scheme or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Scheme's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Scheme's trustees.
- Conclude on the appropriateness of the Scheme's trustees' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Scheme's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Scheme to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Scheme's trustees regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

From the matters communicated with the Scheme's trustees, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report, unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

Non-compliance with the Medical Schemes Act of South Africa

As required by the Council for Medical Schemes, we report that there are no material instances of non-compliance with the requirements of the Medical Schemes Act of South Africa that have come to our attention during the course of our audit.

Audit Tenure

As required by the Council for Medical Schemes' Circular 38 of 2018, Audit Tenure, we report that PricewaterhouseCoopers Inc. has been the auditor of Anglo Medical Scheme for 3 years.

The engagement partner, *Julanie Basson*, has been responsible for Anglo Medical Scheme's audit for 3 years.



PricewaterhouseCoopers Inc.
Director: Julanie Basson
Registered Auditor
Johannesburg
30 April 2021

STATEMENT OF FINANCIAL POSITION

as at 31 December 2020

ANGLO MEDICAL SCHEME

(Registration no. 1012)

	Notes	2020 R'000	2019 R'000
ASSETS			
Non-current assets			
Investments held at fair value through profit or loss	2	1,028,897	1,115,128
Current assets		2,118,209	1,962,373
Investments held at fair value through profit or loss	2	1,880,065	1,709,724
Trade and other receivables	3	8,679	4,754
Cash and cash equivalents	4	229,465	247,895
Total assets		3,147,106	3,077,501
FUNDS AND LIABILITIES			
Accumulated funds		2,882,468	2,823,178
Current liabilities		264,638	254,323
Outstanding risk claims provision	5	23,074	19,450
Medical Savings Account liability	6	231,229	219,655
Trade and other payables	7	10,335	15,218
Total funds and liabilities		3,147,106	3,077,501

STATEMENT OF COMPREHENSIVE INCOME

for the year ended 31 December 2020

ANGLO MEDICAL SCHEME

(Registration no. 1012)

	Notes	2020 R'000	2019 R'000
Risk contribution income	8	516,851	474,682
Relevant healthcare expenditure		(493,926)	(580,446)
Net claims incurred		(480,757)	(577,029)
Risk claims incurred	9	(481,924)	(581,962)
Third party claims recoveries		1,167	4,933
Net (expense)/income on risk transfer arrangements	10	(1,985)	7,565
Risk transfer arrangement fees/premiums paid		(43,897)	(42,031)
Recoveries from risk transfer arrangements		41,912	49,596
Managed care: management services	11	(11,184)	(10,982)
Gross healthcare result		22,925	(105,764)
Administration expenses	12	(33,462)	(32,475)
Net impairment (losses)/gains	13	(301)	182
Net healthcare results		(10,838)	(138,057)
Investment and other income		93,317	216,529
Investment income	14	90,147	215,565
Sundry income	15	3,170	964
Other expenditure		(23,189)	(33,287)
Expenses for asset management services rendered		(13,267)	(16,154)
Interest paid on Medical Savings Accounts		(9,922)	(17,133)
Total comprehensive income for the year		59,290	45,185

STATEMENT OF CHANGES IN FUNDS AND RESERVES

for the year ended 31 December 2020

ANGLO MEDICAL SCHEME

(Registration no. 1012)

	Accumulated funds R'000
Balance as at 1 January 2019	2,777,993
Total comprehensive income for the year	45,185
Balance as at 31 December 2019	2,823,178
Total comprehensive income for the year	59,290
Balance as at 31 December 2020	2,882,468

STATEMENT OF CASH FLOWS
for the year ended 31 December 2020

ANGLO MEDICAL SCHEME
(Registration no. 1012)

	Notes	2020 R'000	2019 R'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash flows from operations before working capital changes	16	(10,838)	(138,056)
Working capital changes			
• (Increase)/decrease in trade and other receivables		(3,973)	1,508
• Increase in Medical Savings Account liability		11,574	25,164
• Increase in outstanding claims provision		3,624	2,446
• Decrease in trade and other payables		(4,883)	(2,075)
Interest paid on Medical Savings Accounts		(9,922)	(17,133)
Sundry income		3,170	964
Net cash outflow from operating activities		(11,248)	(127,182)
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of investments		(1,657,760)	(1,458,026)
Proceeds on sale of investments		1,552,211	1,453,013
Interest received		59,428	59,878
Dividend received		52,206	48,388
Expenses for asset management services rendered		(13,267)	(16,154)
Net cash (outflow)/inflow from investing activities		(7,182)	87,099
NET DECREASE IN CASH AND CASH EQUIVALENTS		(18,430)	(40,083)
Cash and cash equivalents at the beginning of the year		247,895	287,978
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR		229,465	247,895

GENERAL INFORMATION

The Anglo Medical Scheme (the Scheme) offers the insurance of hospital, chronic illness and day-to-day benefits and is administered by Discovery Health (Pty) Ltd, a wholly owned subsidiary of Discovery Limited, listed on the JSE Limited.

The Scheme is a restricted membership medical scheme registered in terms of the Medical Schemes Act No.131 of 1998, as amended, (the Act) and is domiciled in South Africa.

1. PRINCIPAL ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented, unless otherwise stated.

1.1 BASIS OF PREPARATION

The Financial Statements have been prepared in accordance with International Financial Reporting Standards (IFRS), which are set by the International Accounting Standards Board (IASB). The Financial Statements are also prepared in accordance with the Act, which requires additional disclosures for registered medical schemes.

The accounting policies applied in the preparation of these Financial Statements are set out below. These policies have been consistently applied to all years presented, except for changes required by the mandatory adoption of new and revised IFRS, discussed below.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Scheme's accounting policies. The areas involving a higher degree of judgement, or areas where estimates are significant to the Financial Statements, are disclosed in Note 26.

The Financial Statements are prepared in accordance with the going concern principle using the historical cost basis except for certain financial assets and liabilities, which include Financial instruments held at fair value through profit or loss.

All monetary information and figures presented in these financial statements are stated in thousands of rand (R'000), unless otherwise indicated.

1.1 BASIS OF PREPARATION (continued)

IMPLEMENTATION OF NEW STANDARDS

New standards, amendments and interpretations effective in 2020 relevant to the Scheme:

Title	Effective date - financial year commencing on or after
IAS1: Presentation of Financial Statements - Disclosure Initiative: The amendments clarify and align the definition of 'material' and provide guidance to help improve consistency in the application of that concept whenever it is used in IFRS Standards. This amendment had no significant impact on the Annual Financial Statements of the Scheme.	1 Jan 2020
IAS8: Accounting Policies, Changes in Accounting Estimates and Errors - Disclosure Initiative: The amendments clarify and align the definition of 'material' and provide guidance to help improve consistency in the application of that concept whenever it is used in IFRS Standards. This amendment had no significant impact on the Annual Financial Statements of the Scheme.	1 Jan 2020

New standards, amendments and interpretations not yet effective in 2020 relevant to the Scheme:

Title	Effective date - financial year commencing on or after
<p>IFRS 17 - Insurance contracts - The Standard was issued in May 2017 and supersedes IFRS 4 Insurance Contracts.</p> <p>The Standard creates one accounting model for all insurance contracts and establishes principles for the recognition, measurement, presentation and disclosure of insurance contracts issued. The Standard requires insurance contracts to be measured using updated estimates and assumptions that reflect the timing of cash flows and takes into account any uncertainty relating to insurance contracts.</p> <p>The Standard provides for a simplified approach ("premium allocation approach") for the measurement of a group of insurance contracts only if, at the inception of the group, the entity reasonably expects that the simplification will produce measurement of the liability for remaining coverage that would not differ materially from that produced using the general measurement model and if the coverage period is one year or less.</p> <p>Potential impact: The Scheme has assessed the requirements of the standard and agreed a project plan to implement the standard. The coverage period for the Scheme's contracts is one year or less allowing for the premium allocation approach to be applied, resulting in similar treatment to the current accounting. The most notable exceptions relate to the accounting for Personal Medical Savings Accounts, the treatment of onerous contracts and changes to disclosures in the financial statements.</p>	1 Jan 2023

1.2 FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

Items included in the Financial Statements are measured using the currency of the primary economic environment in which the entity operates (functional currency).

The functional and presentation currency of the Scheme is the South African Rand (R).

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets denominated in foreign currencies are recognised in the Statement of Comprehensive Income.

1.3 CLASSIFICATION, RECOGNITION, PRESENTATION AND DERECOGNITION OF FINANCIAL INSTRUMENTS

The Scheme recognises a financial instrument when, and only when, it becomes a party to the contractual provisions of the instrument. The Scheme classifies its financial instruments into the following categories: financial assets or financial liabilities at fair value through profit or loss, and loans and receivables. Loans and receivables are receivables other than those arising from insurance contracts and include sundry accounts receivable and interest receivable. Loans and receivables are disclosed under Trade and other receivables.

The classification depends on the purpose for which the financial instruments are acquired. Management determines the classification of financial instruments at initial recognition. All purchases and sales of financial instruments are recognised on the trade date, which is the date on which the Scheme commits to purchase the financial asset or assume financial liability.

Offsetting financial instruments

This applies where a legally enforceable right to set off exists for recognised financial assets and financial liabilities, and there is an intention to realise the asset and settle the liability simultaneously or to settle on a net basis.

Derecognition of financial assets and liabilities

The Scheme derecognises a financial asset when the contractual rights to the asset expire, where there is a transfer of the contractual rights that comprise the asset, or the Scheme retains the contractual rights of the asset but assumes a corresponding liability to transfer these contractual rights to another party and consequently transfers substantially all the risks and benefits associated with the asset.

If a transfer does not result in derecognition because the Scheme has retained substantially all the risks and rewards of ownership of the transferred asset, the Scheme continues to recognise the transferred asset in its entirety and recognises a financial liability for the consideration received. In subsequent periods, the Scheme recognises any income on the transferred asset and any expense incurred on the financial liability.

1.3 CLASSIFICATION, RECOGNITION, PRESENTATION AND DERECOGNITION OF FINANCIAL INSTRUMENTS (continued)

Where the Scheme neither transfers nor retains substantially all the risks and rewards of ownership of the financial asset, the Scheme determines whether it has retained control of the financial asset. In this case:

- (i) If the Scheme has not retained control, it derecognises the financial asset and recognises separately as assets or liabilities any rights and obligations created or retained in the transfer; and
- (ii) If the Scheme has retained control, it continues to recognise the financial asset to the extent of its continuing involvement in the financial asset.

The Scheme derecognises a financial liability when the contractual obligations are discharged or expire.

1.4 FINANCIAL ASSETS*Investments held at fair value through profit or loss*

The Scheme recognises a financial asset at fair value through profit or loss when upon initial recognition the Scheme designated the asset as fair value through profit or loss.

The Scheme's investment strategy ("business model objective") is determined by means of an allocation across different asset classes and grouping of financial assets into specific portfolios. Independent asset managers manage these portfolios under fully discretionary, active mandates with performance evaluated at portfolio level on a fair value basis. All asset managers are remunerated based on the fair value of the portfolios under management.

The business model objective is achieved through the selling of assets per the documented strategy for realisation of gains with the collection of contractual cash flows being incidental to the primary business model objective. The financial assets are managed together and grouped into specific portfolios. Based on the business model objective the financial assets are measured at fair value through profit and loss.

Financial assets at fair value through profit or loss are initially recognised at fair value and the transaction costs are expensed in the profit or loss section of the Statement of Comprehensive Income.

The fair value of the financial instruments traded in an active market is determined by using quoted market prices or dealer quotes.

Gains or losses arising from subsequent changes in fair value are recognised under Other Income in the Statement of Comprehensive Income within the period in which they arise.

IFRS 12 Unconsolidated investment structures

The Scheme has determined that its investments in pooled funds and collective investment schemes ("funds") are investments in unconsolidated structured entities. The Scheme invests in these funds, whose objectives range from achieving medium to long-term capital growth and whose investment strategy do not include the use of leverage. The funds are managed by unrelated asset managers and apply various investment strategies to accomplish their respective investment objectives.

Trade and other receivables

Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market, other than those the Scheme intends to sell in the short term.

1.4 FINANCIAL ASSETS (continued)

Trade and other receivables (continued)

Receivables are initially recognised at fair value plus transaction costs. The Scheme holds its Insurance Receivables and Other Receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method, less provision for impairment. Trade and other receivables comprise Insurance Receivables, arising from the Scheme's insurance contracts with its members and Other Receivables.

1.5 CASH AND CASH EQUIVALENTS

Cash and cash equivalents are short-term, highly liquid instruments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.

In the Statement of Cash Flows, cash and cash equivalents comprise:

- Money market instruments;
- Call accounts; and
- Current accounts.

Cash and cash equivalents include items held for the purpose of investing and meeting short-term cash commitments and are carried at cost, which, due to their short-term nature, approximates fair value.

1.6 IMPAIRMENT OF FINANCIAL ASSETS

Insurance receivables

The Scheme assesses at each reporting date, whether there is objective evidence that a financial asset is impaired. A financial asset, or group of financial assets, is impaired and impairment losses are incurred if, and only if, there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a "loss event") and that loss event (or events) has an adverse impact on the estimated future cash flows of the financial asset that can be reliably estimated.

The Scheme first assesses whether objective evidence of impairment exists individually for financial assets such as service provider debtors. In the case of assets which are not individually significant, such as contribution debtors, financial assets are grouped on the basis of similar credit characteristics, such as asset type and past-due status. These characteristics are used in the estimation of future cash flows.

If there is objective evidence that an impairment loss on a financial asset has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows discounted at the financial asset's original effective interest rate. The carrying amount of the asset is reduced and the amount of the loss is recognised in surplus or deficit.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed by adjusting the allowance account. The amount of the reversal is recognised in surplus or deficit.

Impairment of Other receivables

Following the implementation of IFRS 9, the Scheme applies the IFRS 9 simplified approach to measure expected credit losses which uses a lifetime expected loss allowance for Other Receivables. To measure the expected credit losses, Other Receivables are grouped based on shared credit risk characteristics and days past due. For the year under review the Scheme does not expect any credit losses on these balances and no provision has been made.

1.7 FINANCIAL LIABILITIES

Financial liabilities are initially recognised at fair value net of transaction costs incurred. After initial recognition, the financial liabilities are measured at amortised cost, using the effective interest method. In addition, the Scheme is not permitted to borrow, in terms of Section 35(6)(c) of the Act. The Scheme therefore has no long-term financial liabilities.

Trade and other payables

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers.

Trade payables are recognized initially at fair value and subsequently measured at amortised cost using the effective interest method.

Insurance payables

Insurance payables are measured initially at fair value (which approximates cost) and subsequently measured at amortised cost using the effective interest method.

Medical Savings Account liabilities

Members' Personal Medical Savings Accounts, represent savings contributions (which are a deposit component of the insurance contracts), and accrued interest thereon, net of any savings claims paid on behalf of members in terms of the Scheme's registered rules. The deposit component has been unbundled since the Scheme can measure the deposit component separately and the Scheme's accounting policies do not otherwise require recognition of all obligations and rights arising from the deposit component.

The savings accounts contain a demand feature and are initially measured at fair value plus transaction costs, which is the amount payable to a member on demand, discounted from the first date that the amount could be required to be paid. Subsequent to initial measurement, the liability is measured at amortised cost using the effective interest rate method.

Unspent savings at year end are carried forward to meet future expenses for which the members are responsible. In terms of the Act, balances standing to the credit of members are refundable only in terms of Regulation 10 of the Act.

Advances on savings contributions are funded from the Scheme's funds, and the risk of impairment is carried by the Scheme.

Interest payable on members' Personal Medical Savings Accounts is expensed when incurred.

1.8 PROVISIONS

The Scheme recognises provisions once the following conditions are met:

- It has a present legal or constructive obligation as a result of past events;
- It is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and
- A reliable estimate of the amount of the obligation can be made.

Provisions are measured as the present value of management's best estimate of the expenditure required to settle the obligation at the reporting date. Where the effect of discounting to present value is material, provisions are adjusted to reflect the time value of money.

Outstanding risk claims provision

Claims outstanding comprise provisions for the Scheme's best estimate of the ultimate cost of settling all claims incurred but not yet reported at the reporting date. Claims outstanding are determined as accurately as possible based on a number of factors. These include previous experience in claims patterns, claims settlement patterns, trends in claims frequency, changes in the claims processing cycle, and variations in the nature and average cost incurred per claim.

Claims handling expenses are not separately accounted for as this service is provided by the Administrator and a fixed fee is paid for the full administration service including claims handling. No provision for claims handling expenses is required as the Scheme has no further liability to the Administrator at year end.

Estimated co-payments and payments from members' Personal Medical Savings Accounts are deducted in calculating the outstanding claims provision. The Scheme does not discount its provision for outstanding claims since the effect of the time value of money is not considered material.

1.9 UNALLOCATED FUNDS

Unallocated funds arise on the receipt of unidentified deposits in favour of the Scheme.

Unallocated funds that have legally prescribed, that is funds older than three years, are written back and are included under Sundry income on the face of the Statement of Comprehensive Income.

A liability for unallocated funds that have not legally prescribed is recognised and disclosed under Trade and other payables. The liability is measured at amortised cost using the effective interest rate method.

1.10 MEMBER INSURANCE CONTRACTS

Contracts under which the Scheme accepts significant insurance risk from another party (the member and respective registered dependants) by agreeing to extend benefits to the member or another beneficiary if a specified uncertain future event (the insured event) adversely affects the member or other beneficiary, are classified as insurance contracts.

The contracts issued compensate the Scheme's members in terms of the Scheme rules for healthcare expenses incurred and are detailed in Note 24.

1.11 RISK CONTRIBUTION INCOME

Gross contributions comprise risk contributions and Medical Savings Account (MSA) contributions.

Risk contributions on member insurance contracts are accounted for monthly when their collection in terms of the insurance contract is reasonably assured. Risk contributions are earned from the date of attachment of insurance risk, over the indemnity period on a straight-line basis and are recognised as revenue.

1.12 RELEVANT HEALTHCARE EXPENDITURE

Relevant healthcare expenditure consists of risk claims incurred and net income or expense from risk transfer arrangements.

Risk Claims incurred

Gross claims incurred comprise the total estimated cost of all claims arising from healthcare events that have occurred in the year and for which the Scheme is responsible to pay from risk or MSA, whether or not reported by the end of the year.

Risk claims incurred (net of claims from members' savings accounts, recoveries from members for co-payments, recoveries from third parties such as motor vehicle accident and forensic recoveries and discounts received from service providers) comprise:

- Risk claims submitted and accrued for services rendered during the year;
- Payments under provider contracts (managed care) for services rendered to members;
- Over or under provision relating to prior year risk claims estimates;
- Risk claims incurred but not yet reported; and
- Risk claims settled in terms of risk transfer arrangements.

Anticipated recoveries under risk transfer arrangements are disclosed separately as assets and are assessed in a manner similar to the assessment of the outstanding risk claims provision and claims reported not yet paid.

1.12 RELEVANT HEALTHCARE EXPENDITURE (continued)**Risk transfer arrangements**

Risk transfer arrangements are contractual arrangements whereby a third party undertakes to indemnify the Scheme against all or part of the loss that the Scheme may incur as a result of carrying on the business of a medical scheme. Risk transfer arrangements do not reduce the Scheme's primary obligations to its members and their dependants, but the arrangements decrease the loss the Scheme may incur as a result of carrying on the business of a medical scheme.

Risk transfer arrangement fees are recognised as an expense over the indemnity period on a straight-line basis.

Risk transfer claims and benefits reimbursed are presented in surplus or deficit and in the Statement of Financial Position on a gross basis. Only contracts that give rise to a significant transfer of insurance risk are accounted for as a risk transfer arrangement. Amounts recoverable under such contracts are recognised in the same year as the related claim.

Assets relating to risk transfer arrangements include balances due under risk transfer arrangements for outstanding claims provisions and claims reported not yet paid. Amounts recoverable under risk transfer arrangements are estimated in a manner consistent with the outstanding claims provisions, claims reported not yet paid, and settled claims associated with the risk transfer arrangement.

Managed care: Management services fees

Managed care: Management services fees comprise amounts paid or payable to a third party for managing the utilisation, costs and quality of health care services to the members of the Scheme. Managed care fees are expensed as incurred.

1.13 SHORT-TERM EMPLOYEE BENEFITS

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.

A liability is recognised for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Scheme has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

1.14 INVESTMENT INCOME

Investment income comprises dividends and interest received and accrued on investments, interest on cash and cash equivalents and fair value movement on financial assets at fair value through profit or loss.

Interest income is recognised on the effective interest method.

Dividend income from investments is recognised when the right to receive payment is established - this is the ex dividend date for equity securities.

Fair value movement on financial assets at fair value through profit or loss include realised and unrealised gains and losses on disposal of assets and revaluation at fair value respectively. The gains and losses are recognised through the statement of comprehensive income in the period in which they arise.

1.15 INTEREST PAID ON MEDICAL SAVINGS ACCOUNTS (MSA)

The interest paid on Medical Savings Accounts is recognised in surplus or deficit using the effective interest method.

1.16 LONG-TERM FUNDING

Additional contributions received from participating employers are intended to compensate for the above average cross-subsidisation of pensioners by active members. Amounts received from participating employers are recognised as other income on a cash receipt basis as there is no legal obligation to refund the amounts to the employer. Long-term funding is recognised in sundry income.

1.17 INCOME TAX

In terms of Section 10(1)(d) of the Income Tax Act, No 58 of 1962, as amended, receipts and accruals of a benefit fund are exempt from income tax. A medical scheme is included in the definition of a benefit fund and consequently the Scheme is exempt from income tax.

1.18 ALLOCATION OF INCOME AND EXPENDITURE TO BENEFIT OPTIONS

The following items are directly allocated to benefit options:

- Risk contribution income;
- Risk claims incurred;
- Risk transfer arrangement fees;
- Administration fees; and
- Managed care: Management services.

For disclosure purposes, the remaining items are apportioned based on the number of members on each option, except for Value Care Plan which is allocated on an average of its proportion of contribution income and membership.

	2020 R'000	2019 R'000
2. INVESTMENTS HELD AT FAIR VALUE THROUGH PROFIT OR LOSS		
Fair value at the beginning of the year	2,824,852	2,712,554
Additions		
Dividend income capitalised	52,206	48,388
Interest income capitalised	56,501	57,534
Acquisition of investments	1,549,053	1,352,104
Disposals		
Expenses for asset management services rendered	(13,267)	(16,154)
Proceeds on disposal of investments	(1,594,027)	(1,280,867)
Movement on revaluation to market value	33,644	(48,707)
Fair value at the end of the year	2,908,962	2,824,852
Less: Short-term portion shown in current assets	(1,880,065)	(1,709,724)
	1,028,897	1,115,128
The investments included above represent investments in:		
Bonds	917,325	897,476
Collective Investment Schemes	435,383	308,312
Commodities	61,602	79,283
Equities	912,960	1,105,282
Linked Insurance Policies	442,778	434,499
Money market instruments	138,914	-
	2,908,962	2,824,852
The investments were managed by the following asset managers at year-end:		
Coronation Asset Management (Pty) Ltd	478,506	646,965
Allan Gray South Africa (Pty) Ltd	380,312	665,655
Ninety One SA (Pty) Ltd	1,565,380	1,512,232
Abax Investments (Pty) Ltd	484,764	-
	2,908,962	2,824,852

A register of investments is available at the registered office of the Scheme

	2020 R'000	2019 R'000
3. TRADE AND OTHER RECEIVABLES		
Insurance receivables		
Contribution receivables	4,381	3,362
Member and service provider claims receivable	671	704
Amount due	2,794	2,781
Less: Allowance for impairment	(2,123)	(2,077)
Forensic receivables	364	380
Receivables arising from insurance contracts	5,416	4,446
Other receivables		
Interest receivable	220	268
Prepaid expenditure	2,017	40
Sundry accounts receivable	1,026	-
Receivables arising from Other receivables	3,263	308
Total trade and other receivables	8,679	4,754

At 31 December 2020, the carrying amounts of loans and receivables approximate their fair values due to the short-term maturities of these assets.

4. CASH AND CASH EQUIVALENTS

Call accounts	109,618	46,049
Current accounts	119,847	70,837
Money market accounts	-	131,009
	229,465	247,895

The weighted average effective interest rate on cash and cash equivalents was 3.94% (2019 - 6.77%). The call accounts have an average maturity of 1 day (2019 - 1 day) as these are used as a clearing facility.

	2020 R'000	2019 R'000
5. OUTSTANDING RISK CLAIMS PROVISION		
Outstanding risk claims provision - not covered by risk transfer arrangements	23,074	19,450
<i>Analysis of movement in outstanding risk claims provision</i>		
Balance at beginning of year	19,450	17,004
Payments in respect of prior year	(18,030)	(16,885)
Over provision in respect of prior year	1,420	119
Movement for the current year	21,654	19,331
Outstanding risk claims provision	23,074	19,450
<i>Analysis of outstanding risk claims provision</i>		
Estimated gross claims	24,330	20,170
Less: Estimated recoveries from MSA (Note 6)	(1,256)	(720)
Total outstanding risk claims provision at year end	23,074	19,450

A liability adequacy test was performed and no additional provision was required.

Basis for determining the outstanding risk claims provision

The outstanding risk claims provision is a provision for the estimated cost of healthcare benefits that have occurred before the reporting date but have not been reported to the Scheme by that date. The provision is determined as accurately as possible based on a number of assumptions which are outlined below.

5. OUTSTANDING RISK CLAIMS PROVISION (continued)

Process used to determine the assumptions

The process used to determine the assumptions is intended to result in a realistic estimate of the most likely or expected outcome. The sources of data used as inputs for the assumptions are internal, using detailed studies of historical claiming patterns to establish a "claims run-off" period per discipline. More emphasis is placed on recent information, particularly where current claims do not appear to follow prior year trends. Where, in prior years, there is insufficient information to make a reliable best estimate of claims development, prudent assumptions are used.

To the extent that historical claims development is used to determine the claims "run-off period", it is assumed that this pattern will occur again in future. There are reasons why this may not be the case, which, insofar as they can be identified, have been allowed for by modifying the methods. Such reasons, inter alia, include:

- Changes in processes that affect the development or recording of claims paid and incurred (such as changes in claims submission mechanisms);
- Changes in membership profile of the Scheme;
- Random fluctuations; and
- Legislative changes (e.g. expansion of the definition of a Prescribed Minimum Benefit ("PMB")/Chronic Disease List ("CDL") condition).

Notified claims are assessed with due regard to the claim circumstances, medical discipline, anticipated development, expected seasonal fluctuations, and information available from managed care: management services (specifically hospital pre-authorisation). The provision is a best estimate based on the most recent information available and may be affected by the differing claims run-off periods between the various medical disciplines. Estimates calculated on the "run-off" period of disciplines with lower utilisations may be subject to a higher degree of volatility due to the relatively small claims history. This is largely negated by the medical disciplines where the majority of the risk claims are incurred and which therefore constitute the bulk of the provision.

Assumptions

The assumptions that have the greatest effect on the measurement of the outstanding risk claims provision, are the claims "run-off periods" for the most recent benefit years (split by discipline), in particular the in-hospital category. The run-off factor relates to the emergence and settlement patterns of risk claims and is expressed as the percentage of risk claims settled in respect of total claims expected to emerge in a specific service month. This factor is then used to project the remainder of the outstanding risk claims relating to the specified service month. A "seasonality factor" is further incorporated into the calculation, also based on past claims experience. Consistent assumptions have been used for assessing the outstanding risk claims provisions for the 2019 and 2020 benefit years.

5. OUTSTANDING RISK CLAIMS PROVISION (continued)

Changes in assumptions

The table below outlines the sensitivity of insured liability estimates to particular movements in assumptions used in the estimation process. It should be noted that this is a deterministic approach with no correlations between the key variables. Where variables are considered to be immaterial, no impact has been assessed for insignificant changes to these variables. Particular variables may not be considered material at present. However, should the materiality level of an individual variable change, assessment of changes to that variable in the future may be required.

An analysis of sensitivity around various scenarios for the general medical insurance business provides an indication of the adequacy of the estimation process. The Trustees believe that the liability for risk claims reported in the statement of financial position is adequate. However, they recognise that the process of estimation is based upon certain variables and assumptions which could differ when claims arise. Consequently, if for example the estimates of the unreceived portion of risk claims costs for the year was 5% inaccurate, the impact on the net result of the Scheme would be as follows:

Impact on reported profits due to changes in key variables:

	Change in variables	Change in claims cost 2020 R'000	Change in claims cost 2019 R'000
In-hospital claims incurred	5%	110	154
Out-of-hospital claims incurred	5%	47	53
Chronic claims incurred	5%	14	16

This analysis has been prepared for a change in run-off factors with other assumptions remaining constant. The change in liability also represents the absolute change in net surplus for the period. It should be noted that an increase in liabilities will result in a decrease in the result and vice versa.

The sensitivity of the estimation process is reduced by the value of the risk claims paid subsequent to the year end related to the period ended 31 December 2020, as detailed in the table below:

	2020 R'000	2019 R'000
Outstanding risk claims provision	23,074	19,450
Portion of outstanding risk claims provision paid to 28 February 2021 (2019: 29 February 2020)	(19,656)	(14,970)
Residual estimate of risk claims incurred but not paid	<u>3,418</u>	<u>4,482</u>

	2020 R'000	2019 R'000
6. MEDICAL SAVINGS ACCOUNT (MSA) LIABILITY		
Balance on MSA liability at the beginning of the year	219,655	194,491
Add:		
MSA contributions received for the current year (Note 8)	76,587	88,145
Transfers received from other medical schemes	110	214
Interest accrued on MSA funds	9,922	17,133
Less:		
Claims paid to or on behalf of members (Note 9)	(62,931)	(70,018)
Refunds on death or resignation	(12,114)	(10,310)
Balance on MSA liability at the end of the year	231,229	219,655

In accordance with the rules of the Scheme, the MSA is underwritten by the Scheme.

MSAs contain a demand feature. In terms of Regulation 10 of the Act, any credit balance on a member's MSA must be paid as a cash benefit when the member terminates his or her membership of the Scheme or benefit option, and enrolls in another benefit option or medical scheme without a MSA, or does not enrol in another medical scheme.

Estimated claims to be paid out of members' MSA in 2021 in respect of claims incurred in 2020 but not yet reported: (Note 5)

<u>1,256</u>	<u>720</u>
--------------	------------

At 31 December 2020, the carrying amount of the MSA liability approximates its fair value, since it is payable on demand. These amounts were not discounted to present values due to their demand feature.

	2020 R'000	2019 R'000
7. TRADE AND OTHER PAYABLES		
Insurance liabilities		
Reported claims not yet paid	4,910	9,398
Total liabilities arising from insurance contracts	<u>4,910</u>	<u>9,398</u>
Financial liabilities		
Balances due to related party - Discovery Health (Pty) Ltd	2,544	2,448
Accruals	2,173	2,631
Unallocated funds	708	741
Total arising from financial liabilities	<u>5,425</u>	<u>5,820</u>
Total trade and other payables	<u>10,335</u>	<u>15,218</u>

At 31 December 2020, the carrying amounts of other liabilities approximate their fair values due to the short-term maturities of these liabilities.

8. RISK CONTRIBUTION INCOME

Gross contributions per registered rules	593,438	562,827
Less: MSA contributions received*	(76,587)	(88,145)
Risk contribution income per statement of comprehensive income	<u>516,851</u>	<u>474,682</u>

* The MSA contributions are received by the Scheme in terms of Regulation 10(1) and the Scheme's registered rules. Refer to Note 6 for more detail.

	2020 R'000	2019 R'000
9. RISK CLAIMS INCURRED		
Claims incurred excluding claims in respect of related risk transfer arrangements		
Current year claims per registered rules	481,289	585,500
Movement in outstanding risk claims provision	21,654	16,884
Over provision in respect of prior year (Note 5)	(1,420)	(2,565)
Adjustment for current year (Note 5)	23,074	19,450
Claims paid from MSA (Note 6)	(62,931)	(70,018)
	<u>440,012</u>	<u>532,366</u>
Claims incurred in respect of risk transfer arrangements		
<i>Netcare 911</i>		
Current year claims	2,393	3,243
<i>Kaelo Prime Cure</i>		
Current year claims	8,989	16,460
<i>Centre for Diabetes and Endocrinology (CDE)</i>		
Current year claims	26,527	25,823
<i>Dental Risk Company</i>		
Current year claims	4,003	4,070
	<u>41,912</u>	<u>49,596</u>
Risk claims per statement of comprehensive income	<u>481,924</u>	<u>581,962</u>

	2020 R'000	2019 R'000
10. NET (EXPENSE)/INCOME ON RISK TRANSFER ARRANGEMENTS		
Capitation fees paid to third party providers	(43,897)	(42,031)
Recoveries under risk transfer arrangements	41,912	49,596
	(1,985)	7,565
Made up as follows:		
Netcare 911 (Pty) Ltd	(185)	728
Capitation fees paid	(2,578)	(2,515)
Recovery from service provider	2,393	3,243
Risk transfer arrangement providing ambulance services (air and land) for members registered on the Managed Care and Standard Care Plans.		
Kaelo Prime Cure (Pty) Ltd	(3,616)	5,236
Capitation fees paid	(12,605)	(11,224)
Recovery from service provider	8,989	16,460
Risk transfer arrangement providing an agreed structure of day-to-day benefits, including treatment of chronic conditions, for members registered on the Value Care Plan. The contract excludes the provision of treatment, per event, for any hospital admissions above R71,665 in private facilities.		
Centre for Diabetes and Endocrinology	1,832	1,413
Capitation fees paid	(24,695)	(24,410)
Recovery from service provider	26,527	25,823
Risk transfer arrangement covering treatment for members registered on the Managed Care and Standard Care Plans, diagnosed with diabetes including diabetic related hospital admissions.		
Dental Risk Company	(16)	188
Capitation fees paid	(4,019)	(3,882)
Recovery from service provider	4,003	4,070
Risk transfer arrangement for protection against and transfer of all risks relating to dental benefits for members registered on the Standard Care Plan.		
	(1,985)	7,565

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2020

ANGLO MEDICAL SCHEME

(Registration no. 1012)

10. NET INCOME ON RISK TRANSFER ARRANGEMENTS (continued)

The Scheme has entered into selective risk transfer arrangements with these third party providers in order to reduce its exposure to claims risk and receive specialist case management. These arrangements form a relatively small component of the total claims cost of the Scheme.

The cost of providing the capitated services was estimated by calculating Per Life Per Month (PLPM) estimates for services covered under these risk transfer arrangements and multiplying them by the number of members exposed for the period to the respective programmes.

	2020	2019
	R'000	R'000
11. MANAGED CARE: MANAGEMENT SERVICES		
Chronic medicine management services	1,106	1,153
Disease management services	3,224	3,066
Hospital management services	3,123	3,136
Pharmaceutical benefit management services	1,009	980
Provider network management services	2,722	2,647
	11,184	10,982

12. ADMINISTRATION EXPENSES

Administration fees	20,683	20,110
Staff costs	3,695	3,321
Principal Officer remuneration and related expenses	2,431	2,304
Consulting fees	2,078	1,919
Trustee remuneration and considerations	1,159	1,142
Electronic checking fees	1,154	1,211
Publications	653	640
Audit fees	499	479
Council for Medical Schemes expenses	366	354
Head office rental and management fees	283	283
General expenses	246	179
Travel and entertainment	215	365
Trustee election expenses	-	168
	33,462	32,475

	2020 R'000	2019 R'000
13. NET IMPAIRMENT (LOSSES)/GAINS		
Insurance receivables		
Members claims debt	(91)	(120)
Movement in allowance account	164	(125)
(Impairment write off)/impairment reversal	(255)	5
Suppliers claims debt	(210)	302
Movement in allowance account	(210)	302
	(301)	182
14. INVESTMENT INCOME		
Interest income on current accounts	2,879	2,357
Income on other	77,980	285,950
Interest income	56,501	57,534
Dividend income	52,206	48,388
Net realised (losses)/gains on fair value adjustments	(30,727)	180,028
Movement in fair value adjustments	9,288	(72,743)
	90,147	215,564
15. SUNDRY INCOME		
Long-term funding	968	922
Prescribed income	2,202	42
	3,170	964

	2020 R'000	2019 R'000
16. CASH FLOWS FROM OPERATING ACTIVITIES BEFORE WORKING CAPITAL CHANGES		
Net surplus for the year	59,290	45,185
Adjustments for:		
Investment income excluding fair value adjustments (Note 14)	(80,859)	(288,307)
- interest income on current accounts	(2,879)	(2,357)
- income on other	(77,980)	(285,950)
Interest paid on Medical Savings Accounts	9,922	17,133
Movement in fair value adjustments (Note 14)	(9,288)	72,743
Sundry income (Note 15)	(3,170)	(964)
Expenses for asset management services rendered	13,267	16,154
Cash flows from operations before working capital changes	(10,838)	(138,056)

17. FIDELITY COVER

Anglo Medical Scheme, its Trustees and employees are covered by the insurer of the sponsoring employer company, Anglo American plc and Subsidiaries and Corporate Trustee Company (ies), for professional indemnity to an aggregated limit of USD 35,000,000 for the period 1st July 2020 to 1st July 2021.

18. COMMITMENTS AND CONTINGENT LIABILITIES

The Scheme does not have any commitments or contingent liabilities outstanding at 31 December 2020 (2019: Nil).

19. CONTINGENT ASSET

As at 31 December 2020, the Scheme had pending motor vehicle accident medical claims submitted to the Road Accident Fund (RAF) for assessment. This will only be accounted for when an amount is certain to be received from the RAF.

20. EVENTS AFTER THE REPORTING DATE

There have been no facts or circumstances of a material nature that have occurred between the accounting date and the date of this report.

21. RELATED PARTY TRANSACTIONS

The Scheme is controlled by the Board of Trustees who are appointed by the participating employers or elected by the members of the Scheme.

Key management personnel

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Scheme. Key management personnel include the Board of Trustees and the Principal Officer.

Close family members include close family members of the Board of Trustees and Principal Officer, and are also related parties.

Parties with significant influence over the Scheme

Discovery Health (Pty) Ltd has significant influence over the Scheme, as it provides administration and managed care services as well as financial and operational information on which policy decisions are based.

The Scheme contracted with Discovery Third Party Recovery Services (Pty) Ltd (DTPRS), a wholly owned subsidiary of Discovery Health (Pty) Ltd, to manage the identification and collection of third party recoveries from the Road Accident Fund.

The Scheme has a risk transfer arrangement contract in place with Kaelo Prime Cure (Pty) Ltd making provision for an agreed structure of day-to-day benefits, including treatment of chronic conditions, for members registered on the Value Care Plan.

Medikredit (Pty) Ltd has significant influence over the Scheme, as it provides managed care services to the Scheme.

Anglo Corporate Services South Africa (Pty) Ltd receives from the Scheme market related reimbursement for head office rental and management services provided.

Transactions with related parties

The following provides the total amount in respect of transactions, which have been entered into with related parties for the relevant year.

	2020	2019
	R'000	R'000
<i>Transactions with key management personnel</i>		
Statement of Comprehensive Income transactions		
Gross contributions received	1,816	1,668
Gross claims paid	953	1,154
Interest on MSA balances	9	7
Key management personnel remuneration	6,126	5,625
Trustee remuneration and considerations	1,159	1,142
Statement of Financial Position		
Medical Savings Accounts	225	101

21. RELATED PARTY TRANSACTIONS (continued)

The terms and conditions of the above related party transactions were as follows:

<i>Transactions</i>	<i>Nature of transactions and their terms and conditions</i>
Gross contributions received	This constitutes the contributions paid by the related party as a member of the Scheme, in their individual capacity. All contributions were on the same terms as applicable to all members.
Gross claims paid	This constitutes amounts claimed by the related parties, in their individual capacity as members of the Scheme. All claims were paid out in terms of the rules of the Scheme, as applicable to all members.
Interest on MSA balances	Interest is earned on positive MSA balances at an interest rate equal to the Repo Rate. At 31 December 2020 this rate was 3,50% (2019: 8,50%) per annum.
Medical Savings Accounts	The amounts owing to the related parties relate to MSA balances. In line with the terms applied to all members, the balances earn interest monthly at predetermined interest rates, on an accrual basis. The amounts are all current and are payable on demand if an appropriate claim is received, or if the member resigns from the Scheme, as applicable to all members.

	2020	2019
	R'000	R'000
<i>Transactions with parties with significant influence over the Scheme</i>		
Statement of Comprehensive Income transactions		
Administration fees	20,683	20,110
Electronic checking fees	1,154	1,211
Head office rental and management fees	283	283
Managed care: management services fees	10,078	9,819
Risk transfer arrangement fees	12,605	11,224
Statement of Financial Position		
Balance due to Discovery Health (Pty) Ltd	2,544	2,448
Balance due to Medikredit (Pty) Ltd	104	332
Balance due to Kaelo Prime Cure (Pty) Ltd	1,103	1,001
Head office rental	27	36
Investment in employers	58,346	26,329

21. RELATED PARTY TRANSACTIONS (continued)

The terms and conditions of the above transactions with entities with significant influence over the Scheme were as follows:

Administration and managed care agreements with Discovery Health

The administration and managed care management service agreements are in terms of the rules of the Scheme and in accordance with instructions given by the Board of Trustees. The agreements are automatically renewed each year unless notification of termination is received or following the cancellation of the Administrator's accreditation or the issue of a lawful directive to this effect by the Council for Medical Schemes in terms of the Act. The Scheme and the Administrator/Managed Healthcare Organisation shall be entitled to terminate the agreement by giving notice in writing of not less than 90 days and not more than 180 days. The outstanding balance bears no interest and is due within 7 days.

Managed care agreement with Medikredit (Pty) Ltd

The managed care agreement is in terms of the rules of the Scheme and in accordance with instructions given by the Board of Trustees. The agreement is automatically renewed each year unless notification of termination is received or following the cancellation of the managed care organisation's accreditation or the issue of a lawful directive to this effect by the Council for Medical Schemes in terms of the Act. The Scheme and the Managed Healthcare Organisation shall be entitled to terminate the agreement by giving notice in writing of not less than 90 days. The outstanding balance bears no interest.

Risk transfer arrangement agreement with Kaelo Prime Cure (Pty) Ltd

The agreement is in terms of the rules of the Scheme and in accordance with instructions given by the Board of Trustees. The agreement continues indefinitely unless notification of termination is received or following the cancellation of the organisation's accreditation or the issue of a lawful directive to this effect by the Council for Medical Schemes in terms of the Act. The Scheme and the Organisation shall be entitled to terminate the agreement by giving notice in writing of not less than 90 days. The outstanding balance bears no interest.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2020

ANGLO MEDICAL SCHEME

(Registration no. 1012)

22. TRUSTEE REMUNERATION AND CONSIDERATIONS

Trustees	Fees for meeting attendance		Disbursements		Accommodation, travelling and meals		Total	
	2020 R'000	2019 R'000	2020 R'000	2019 R'000	2020 R'000	2019 R'000	2020 R'000	2019 R'000
Abramowitz DE*	75	52	-	-	-	-	75	52
Coetzer JP*	82	52	-	-	-	-	82	52
Elliott CC* ^	83	60	15	-	-	-	98	60
Farrell MR	34	85	-	14	-	5	34	104
Fox Dr FH	120	15	15	-	1	1	136	16
Hosking S*	-	78	-	-	-	34	-	112
Howell GA*	-	65	-	-	-	-	-	65
Laubscher PA*	-	73	-	-	-	-	-	73
Liston JB*	104	52	-	-	-	-	104	52
Mamabolo NM*	96	6	-	-	-	-	96	6
Mason-Gordon NJ*	86	47	-	-	-	-	86	47
Mbekeni Dr CWS*	-	52	-	-	-	-	-	52
McCallum DR	118	93	15	-	11	61	144	154
Mckie Thomson CC	-	102	-	14	-	-	-	116
Mhlongo PQ*	103	13	-	-	-	-	103	13
Moodley R*	76	-	-	-	-	-	76	-
Preston GJ	-	78	-	14	1	24	1	116
Thompson HM*	62	-	-	-	-	-	62	-
Van der Bijl BD*	62	52	-	-	-	-	62	52
TOTAL	1,101	975	45	42	13	125	1,159	1,142

* Trustees fees ceded to employers

^ Not ceded in 2020

23. (DEFICIT)/SURPLUS PER BENEFIT OPTION

2020	MANAGED CARE PLAN R'000	STANDARD CARE PLAN R'000	VALUE CARE PLAN R'000	TOTAL R'000
Risk contribution income	288,797	213,148	14,906	516,851
Relevant healthcare expenditure	(310,388)	(170,353)	(13,185)	(493,926)
Net claims incurred	(305,632)	(165,555)	(9,570)	(480,757)
Risk claims incurred	(306,371)	(165,959)	(9,594)	(481,924)
Third party claims recoveries	739	404	24	1,167
Net income/(expense) on risk transfer arrangements	978	652	(3,615)	(1,985)
Risk transfer arrangement fees/premiums paid	(15,790)	(15,502)	(12,605)	(43,897)
Recoveries from risk transfer arrangements	16,768	16,154	8,990	41,912
Managed care: management services	(5,734)	(5,450)	-	(11,184)
Gross healthcare result	(21,591)	42,795	1,721	22,925
Administration expenses	(16,783)	(15,998)	(681)	(33,462)
Net impairment losses	(142)	(131)	(28)	(301)
Net healthcare results	(38,516)	26,666	1,012	(10,838)
Investment and other income	43,224	41,089	9,004	93,317
Other expenditure	(11,232)	(10,677)	(1,280)	(23,189)
Net (deficit)/surplus for the year	(6,524)	57,078	8,736	59,290
Number of members at year-end	3,980	3,862	871	8,713

23. (DEFICIT)/SURPLUS PER BENEFIT OPTION (continued)

2019	MANAGED CARE PLAN R'000	STANDARD CARE PLAN R'000	VALUE CARE PLAN R'000	TOTAL R'000
Risk contribution income	266,032	195,809	12,841	474,682
Relevant healthcare expenditure	(370,622)	(197,859)	(11,965)	(580,446)
Net claims incurred	(366,140)	(193,688)	(17,201)	(577,029)
Risk claims incurred	(369,270)	(195,344)	(17,348)	(581,962)
Third party claims recoveries	3,130	1,656	147	4,933
Net income on risk transfer arrangements	1,283	1,046	5,236	7,565
Risk transfer arrangement fees/premiums paid	(16,823)	(13,984)	(11,224)	(42,031)
Recoveries from risk transfer arrangements	18,106	15,030	16,460	49,596
Managed care: management services	(5,765)	(5,217)	-	(10,982)
Gross healthcare result	(104,590)	(2,050)	876	(105,764)
Administration expenses	(16,729)	(15,127)	(619)	(32,475)
Net impairment losses	88	79	15	182
Net healthcare results	(121,231)	(17,098)	272	(138,057)
Investment and other income	123,862	84,484	8,183	216,529
Other expenditure	(19,044)	(12,986)	(1,257)	(33,287)
Net (deficit)/surplus for the year	(16,412)	54,400	7,197	45,185
Number of members at year-end	4,192	3,849	818	8,859

24. INSURANCE RISK MANAGEMENT REPORT

Nature and extent of risks arising from insurance contracts

The Scheme issues contracts that transfer insurance risk. The primary insurance activity carried out by the Scheme indemnifies covered members and their dependants against the risk of loss arising as a result of the occurrence of a health event, in accordance with the Scheme Rules and legislative requirements.

This section summarises these risks and the way in which they are managed.

Insurance risk

The risk under any insurance contract can be expressed as the probability that an insured event occurs, multiplied by the expected amount of the resulting claim. Insurance events are random and therefore the actual number and size of events during any year are unknown and vary from those estimated. The principal risk that the Scheme faces under its insurance contracts is that the actual claim payments exceed the projected amount of the insurance liabilities. This could occur because the frequency and severity of claims are greater than estimated.

A larger number of members will result in smaller variability of the actual claims experience relative to expected levels. This is because adverse experience is diluted by a larger group of members whose claims are more stable and thus predictable.

Factors that aggravate insurance risk include unanticipated demographic movements, adverse experience due to an unexpected epidemic, changes in members' disease profiles, unexpected price increases, prevalence of fraud, supplier-induced demand and the cost of new technologies or drugs.

The risks that the Scheme faces can be discussed for the different benefits offered. The three main types of benefits offered by the Scheme in return for monthly contributions are indicated below:

Hospital benefits

In-hospital benefits cover all costs incurred by members, while they are in hospital to receive authorised treatment for certain medical conditions. This includes accommodation, theatre, professional services, medication, equipment and consumables.

Chronic benefits

Prescribed Minimum Benefits (PMB): medication and consultations including defined procedures are funded i.e. high blood pressure, cholesterol and asthma. Non-PMB chronic conditions: medication funded.

Day-to-day benefits

Day-to-day benefits cover the cost of out of hospital medical attention, such as visits to general practitioners, dentists and specialists as well as prescribed non-chronic medicines other than those funded from members' savings accounts.

24. INSURANCE RISK MANAGEMENT REPORT (continued)

The risks associated to the Scheme with the types of benefits offered to members are addressed below:

Hospital benefit risk

The main factors affecting the frequency and severity of hospital claims are the number of admissions and the cost per event. An increase in the frequency and severity of claims result in an increase in the cost of claims.

An increase in the admission rate is often linked to increases in the number of beneficiaries at older ages. The increase in cost per event is driven by annual tariff and other cost increases. An increased cost per event can also be caused by an increased case-mix, severity of admissions and the introduction of new hospital-based technologies.

The following table shows various factors that impact hospital claims:

Key indicators	2020	2019	% Increase/ (decrease)
Length of stay (days)	4.55	4.15	9.6%
Average hospital cost per admission (R)	41,080	34,879	17.8%
Total cost per event (R)	66,936	55,387	20.9%
Total cost per life per month (R)	771	981	(21.4%)
Admissions per 1 000 lives	225	337	(33.2%)

Chronic benefit risk

The main factors impacting the frequency and severity of chronic claims are the number of claimants and the cost per claimant. An increase/decrease in the number of claimants results in an increase/decrease in the frequency of claims. Higher increases in claimants and severity of claims may be attributed to increases in the number of claimants at older ages or beneficiaries who are more sickly. Conversely, lower prevalence rates may be indicative of a healthier membership.

The mix between the various chronic conditions impacts the frequency and severity of claims. Certain factors that impact chronic cost are shown below:

Key indicators	2020	2019	% Increase/ (decrease)
Claimants per 1 000 lives	30.96	31.79	(2.6%)
Amount paid per life per month	168	179	(6.1%)

24. INSURANCE RISK MANAGEMENT REPORT (continued)

Day-to-day benefit risk

The main factors impacting the frequency and severity of day-to-day claims are the number of claimants and the cost per claimant. An increase in the cost of claims results from an increase in the frequency and/or severity of claims. The mix of members between the different benefit options will also have an impact on the claims.

Risk management

The Scheme has various initiatives that are used to manage risks associated with claims experience. These include:

- All hospital admissions have to be authorised. There have also been amendments to the pre-authorisation length of stay benchmarks;
- Case managers monitor members with hospital stays that are longer than expected to ensure that members are discharged at appropriate times;
- Out-of-hospital programs addressing risk and preventing re-admissions; and
- Protocols guiding access to expensive technologies and medication.

Concentration of insurance risk

The following table summarises the concentration of insurance risk per beneficiary per annum, with reference to the carrying amount, net of adjustments, of the insurance claims incurred by age group and in relation to the type of risk covered/benefits provided:

2020		Hospital	Chronic	Day-to-day	Total
Age grouping (in years)		R	R	R	R
< 26		3,042	236	2,153	5,431
26 - 35		5,913	429	4,467	10,809
36 - 50		9,158	1,289	5,690	16,137
51 - 65		17,080	2,953	9,048	29,081
> 65		39,979	4,862	12,997	57,838

2019		Hospital	Chronic	Day-to-day	Total
Age grouping (in years)		R	R	R	R
< 26		5,676	286	2,452	8,413
26 - 35		7,376	541	4,512	12,428
36 - 50		10,946	1,430	6,096	18,472
51 - 65		19,247	3,178	9,006	31,432
> 65		48,372	5,008	13,064	66,444

24. INSURANCE RISK MANAGEMENT REPORT (continued)***Risk transfer arrangements***

The Scheme has four risk transfer agreements in which suppliers are paid to provide certain minimum benefits to Scheme members. These arrangements fix the cost to the Scheme of providing these benefits.

The first risk transfer arrangement (Kaelo Prime Cure) covers day to day expenditure, including treatment of chronic conditions, and hospital admissions under R71,665 for members on the Value Care Plan. The second arrangement (Netcare 911), provides emergency transport to all members on the Standard Care and Managed Care plans. The third arrangement with CDE covers the treatment for members diagnosed with diabetes (type I and II) on the Standard Care and Managed Care plans and the fourth arrangement with Dental Risk Company provides dental benefits to Standard Care plan members.

Risk in terms of risk transfer arrangements

The Scheme does however remain liable to its members to provide the benefits. If any supplier fails to meet the obligations of the risk transfer arrangement, the Scheme will cover the cost of the benefit.

When selecting a supplier, the Scheme assesses their ability to provide the relevant service. The Scheme also monitors the performance of the suppliers, assesses the quality of care provided and has access to data on the underlying fee-for-service claims that are included in the arrangement.

Claims development

Detailed claims development tables are not presented as the uncertainty regarding the amount and timing of claim payments is typically resolved within one year and in the majority of cases within three months. At year end, a provision is made for those claims outstanding that are not yet reported at that date.

The methodology followed in determining the outstanding claims provision is the generally accepted actuarial methodology of chain ladder estimation. This methodology is the most objective, but the accuracy of the estimate is sensitive to changes in the average time from treatment to payment of claims. For hospital claims in the latest service month, another method using the estimated cost per event and pre-authorised admissions is also utilised/applied.

The table below outlines the sensitivity of insured liability estimates to particular movements in assumptions used in the estimation process. It should be noted that this is a deterministic approach with no correlations between the key variables. For each sensitivity illustrated, all other assumptions have been left unchanged.

Impact on the outstanding claims provision and reported surplus or deficit caused by changes in key variables:

	Change in variable	2020 R'000	2019 R'000
In-hospital claims incurred		110	154
Chronic claims incurred	5% change in claims cost	47	53
Out-of-hospital claims incurred		14	16

25. FINANCIAL RISK MANAGEMENT REPORT**Overview**

The Scheme is exposed to financial risk through its financial assets, financial liabilities and insurance liabilities. In particular the financial risk is that the proceeds, for any reason, from its financial assets are not sufficient to fund the obligations arising from its insurance contracts. The most important components of financial risk include market risk, interest rate risk, credit risk and liquidity risk.

The Scheme's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potentially adverse effects on the financial performance of the investments that the Scheme holds to meet its obligations to its members.

The Board of Trustees has overall responsibility for the establishment and oversight of the Scheme's risk management framework.

The Scheme manages these risks through various risk management processes. These processes have been developed to ensure that the long-term investment return on assets supporting the insurance liabilities is sufficient to contribute towards funding members' reasonable benefit expectations.

The Scheme manages the financial risks as follows:

- The Investment Committee, a committee (the Committee) of the Board of Trustees, determines, recommends, implements and maintains investment policies and procedures. The Committee advises the Board of Trustees on the strategic and operating matters in respect of the investment of Scheme funds and meets at least quarterly;
- The Scheme has appointed reputable external asset managers to manage its investments and their performance is monitored regularly; and
- An external asset consulting company has been appointed to assist in formulating the investment strategy and to provide ongoing reporting and monitoring of the asset managers.

25. FINANCIAL RISK MANAGEMENT REPORT (continued)**Market risk**

Market risk is the risk that changes in market variables, such as foreign exchange rates, interest rates and equity prices, will affect the Scheme's income or the value of its holdings in financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

The Scheme's insurance liabilities are settled within one year and the Scheme does not discount insurance liabilities. Consequently, changes in market interest rates would not affect the Scheme's surplus or deficit arising from changes in the insurance liability.

Currency risk

Currency risk is the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The Scheme operates in South Africa and therefore its cash flows are denominated in South African Rand (ZAR). In terms of the diversified investment strategy operated by the investment committee and the restrictions imposed by the Medical Schemes Act, the Scheme has a relatively small number of investments off-shore. The Scheme is exposed to foreign exchange risk arising from currency exposures. 9,9% (2019: 5,1%) of total investments were invested in foreign investments.

The following table illustrates the concentration of direct currency risk to which the Scheme is currently exposed:

As at 31 December 2020			
	ZAR R'000	Foreign currency R'000	TOTAL R'000
Investments held at fair value through profit or loss	2,615,607	293,355	2,908,962
Cash and cash equivalents	212,505	16,960	229,465
	<u>2,828,112</u>	<u>310,315</u>	<u>3,138,427</u>
As at 31 December 2019			
	ZAR R'000	Foreign currency R'000	TOTAL R'000
Investments held at fair value through profit or loss	2,733,305	91,547	2,824,852
Cash and cash equivalents	183,076	64,819	247,895
	<u>2,916,381</u>	<u>156,366</u>	<u>3,072,747</u>

There has been significant movement in the ZAR against major currencies during the year. Holding all other variables constant, and adjusting currencies with 10% for the year, the table below illustrates the impact to the value of investments of the Scheme:

	% ZAR movement	2020 R'000	2019 R'000
Foreign currency	10%	31,032	15,637

25. FINANCIAL RISK MANAGEMENT REPORT (continued)***Equity risk***

Equity risk is the risk that the value of a financial instrument will fluctuate as a result of changes in the market place.

Equities are reflected at market values, which are susceptible to fluctuations. The Scheme manages its equity risk by employing the following procedure:

- Mandating a specialist fund manager to invest in equities, where there is an active market and where access is gained to a broad spectrum of financial information relating to the companies invested in;
- Diversifying across many securities to reduce risk. Diversification is guided by the Medical Schemes Act; and
- Considering the risk-reward profile of holding equities and bearing the risk in order to obtain higher expected returns on assets.

If the South African equities market were to move by 10%, assuming all other variables remain constant, the below table illustrates the impact to the value of investments of the Scheme:

	% SA market movement	2020 R'000	2019 R'000
Investments held at fair value through surplus or deficit: Equities	10%	91,296	110,528

25. FINANCIAL RISK MANAGEMENT REPORT (continued)

Interest rate risk

Interest rate risk is the exposure that the Scheme has to changes in interest rates. As the Scheme holds no debt with the exception of the members' saving liability on which interest is paid, the main exposure to the Scheme would be a reduction in interest income on investments if interest rates were to decrease. In order to reduce the impact of any potential interest rate changes, the Scheme holds a diversified portfolio of both long and short term investments.

The table summarises the Scheme's exposure to interest rate risks. Included in the table are the Scheme's investments at carrying amounts, categorised by the earlier of contractual repricing or maturity dates:

As at 31 December 2020	0 - 3 months R'000	3 - 12 months R'000	> 12 months R'000	Total R'000
Cash and cash equivalents	229,465	-	-	229,465
Investments held at fair value through profit or loss	1,852,831	27,234	1,028,897	2,908,962

As at 31 December 2019	0 - 3 months R'000	3 - 12 months R'000	> 12 months R'000	Total R'000
Cash and cash equivalents	115,418	131,147	1,330	247,895
Investments held at fair value through profit or loss	1,692,123	17,601	1,115,128	2,824,852

The following table summarises the effective interest rate for monetary financial instruments:

	2020 %	2019 %
Cash and cash equivalents - Medical Scheme assets	3.94%	6.77%

A change of 100 basis points in interest rates at the reporting date would have an effect on surplus or deficit by the amounts shown below. This analysis assumes that all other variables remain constant. The analysis is performed on the same basis as 2019.

	% change in interest rates	2020 R'000	2019 R'000
Cash and cash equivalents - Medical Scheme assets	1%	8,771	8,847

25. FINANCIAL RISK MANAGEMENT REPORT (continued)**Capital management**

The Scheme is subject to the capital requirement imposed by Regulation 29 (2) of the Act, which requires a minimum solvency ratio of accumulated funds expressed as a percentage of gross contributions to be 25%.

The Scheme's objectives when managing capital are to maintain the capital requirements of the Act, and to safeguard the Scheme's ability to continue as a going concern in order to provide benefits for its stakeholders.

The calculation of the regulatory capital requirement is set out below:

	2020 R'000	2019 R'000
Total Members' Funds per the Statement of Financial Position	2,882,468	2,823,178
Less: cumulative unrealised net gain on measurement of investments to fair value	(211,852)	(202,566)
Accumulated funds per Regulation 29	2,670,617	2,620,612
Gross contribution income (R'000)	593,438	562,827
Solvency margin		
= Accumulated funds/gross contribution income x 100	450.02%	465.62%

Investment risk

Investment risk is the risk that the investment returns on accumulated assets will not be sufficient to cover future liabilities. Continuous monitoring takes place to ensure that appropriate assets are held where the Scheme's liabilities are dependent upon the performance of the investment portfolio and that a suitable match of assets exists for all liabilities.

The Scheme's investment objectives are to maximise the return on its investments on a long-term basis at minimal risk, subject to any constraints imposed by legislation or the Board of Trustees. The Scheme diversifies its investment portfolio by investing in short-term deposits via pooled investment vehicles, bond, money market and equity portfolios managed by reputable asset managers.

To assist the Regulator in monitoring the Scheme's compliance with Annexure B of the Act, the Scheme submits detailed investment schedules to the Council for Medical Schemes, supplemented by the Scheme's asset manager's reports on a quarterly basis.

25. FINANCIAL RISK MANAGEMENT REPORT (continued)

Breakdown of investments

The following table compares the fair value and carrying amounts of financial assets and financial liabilities per class of assets and liabilities:

As at 31 December 2020	Financial assets and liabilities at fair value through profit or loss R'000	Loans and receivables R'000	Insurance receivables and (payables) R'000	Financial liabilities at amortised cost R'000	Total carrying amount R'000	Fair value amount R'000
Investments						
Held at fair value through profit or loss	2,908,962	-	-	-	2,908,962	2,908,962
Cash and cash equivalents	-	229,465	-	-	229,465	229,465
Trade and other receivables	-	3,263	5,416	-	8,679	8,679
Outstanding risk claims provision	-	-	(23,074)	-	(23,074)	(23,074)
Medical Savings Account liability	-	-	(231,229)	-	(231,229)	(231,229)
Trade and other payables	-	-	(4,910)	(5,425)	(10,335)	(10,335)
	2,908,962	232,728	(253,797)	(5,425)	2,882,468	2,882,468
As at 31 December 2019	R'000	R'000	R'000	R'000	R'000	R'000
Investments						
Held at fair value through profit or loss	2,824,852	-	-	-	2,824,852	2,824,852
Cash and cash equivalents	-	247,895	-	-	247,895	247,895
Trade and other receivables	-	308	4,446	-	4,754	4,754
Outstanding risk claims provision	-	-	(19,450)	-	(19,450)	(19,450)
Medical Savings Account liability	-	-	(219,655)	-	(219,655)	(219,655)
Trade and other payables	-	-	(9,398)	(5,820)	(15,218)	(15,218)
	2,824,852	248,203	(244,057)	(5,820)	2,823,178	2,823,178

25. FINANCIAL RISK MANAGEMENT REPORT (continued)

Assets measured at fair value

The fair value assets are classified using a fair value hierarchy that reflects the significance of the inputs used in determining the measurements:

- Level 1: These are assets measured using quoted prices in an active market
- Level 2: These are assets measured using inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and
- Level 3: These are assets measured using inputs that are not based on observable market data.

Fair value hierarchy for financial assets measured at fair value

	2020 R'000	2019 R'000
Level 1		
Bonds	917,325	897,476
Commodities	61,602	79,283
Equities	912,960	1,105,282
Level 2		
Collective Investment Schemes	435,383	308,312
Linked Insurance Policies	442,778	434,499
Money market instruments	138,914	-
	<u>2,908,962</u>	<u>2,824,852</u>

Credit risk

Credit risk is the risk of financial loss to the Scheme, if a counterparty to a financial instrument fails to meet its contractual obligations.

Key areas where the Scheme is exposed to credit risk are:

- Trade and other receivables comprising insurance receivables and other receivables. The main components of insurance receivables are in respect of contributions due from members and amounts recoverable from members and suppliers in respect of claims debt. The Scheme has exposure from its other receivables;
- Financial assets are valued at fair value through profit or loss. These assets comprise bond instruments, commodities and equities. The Scheme is exposed to the issuer's credit standing on these instruments. Exposure to credit risk is monitored and minimum credit ratings for these investments are set. Reputable asset managers have been appointed to manage these instruments; and
- Cash and cash equivalents comprise of fixed deposits, deposits held on call with banks and other short term liquid investments. The risks associated with these deposits are managed by monitoring the Scheme's exposure to external financial institutions against approved deposit limits per institution.

25. FINANCIAL RISK MANAGEMENT REPORT (continued)

Credit risk (continued)

The Scheme's Trade and other receivables at 31 December 2020 comprise:

	2020 R'000	2019 R'000
Insurance receivables	5,416	4,446
Contributions receivable (a)	4,381	3,362
Member and service provider claims receivables (b)	2,794	2,781
Less: Allowance for Impairment losses	(2,123)	(2,077)
Forensic receivables	364	380
Other receivables	3,263	308
Interest receivable	220	268
Prepaid expenditure	2,017	40
Sundry accounts receivable	1,026	-

- a. Contributions receivable are not credit rated by the Scheme as exposure to any single member is insignificant. Contributions receivable comprise amounts receivable from individuals and corporates and are collected by means of debit orders or cash payments. They are actively pursued if not received within three days of becoming due. Benefits are suspended on member accounts when contributions have not been received for 30 days and membership is terminated when contributions have not been received for 60 days.
- b. Member and service provider claims receivable are amounts recoverable in respect of claims debt. They are not credit rated by the Scheme as exposure to any single party is insignificant. Member receivables are separated between active and withdrawn members.

Exposure to credit risk

The carrying amount of Trade and other receivables represents the maximum credit exposure.

The Scheme ages and pursues unpaid accounts on a monthly basis. The tables below highlight insurance receivables within Trade and other receivables which are due, past due (by number of days) and impaired.

	Gross 2020 R'000	Impairment 2020 R'000	Gross 2019 R'000	Impairment 2019 R'000
Insurance receivables				
Not past due	4,737	-	3,772	-
Past due 0 - 30 days	122	-	166	-
Past due 31 - 60 days	92	-	47	-
Past due 61 - 150 days	277	251	315	304
151 days to more than 1 year	2,311	1,872	2,223	1,773
	7,539	2,123	6,523	2,077

25. FINANCIAL RISK MANAGEMENT REPORT (continued)**Credit risk (continued)*****Impairment losses***

The Scheme establishes an allowance for impairment that represents its estimate of anticipated losses in respect of Trade and other receivables. The provision is based on the expected difference between the current carrying amount and the amount recoverable from the counterparties.

Below is the movement in the impairment for each component of Trade and other receivables during the year ended 31 December 2020:

	Member and service provider claims R'000
Balance as at 1 January 2020	2,077
Movement in impairment allowance	301
Amounts utilised during the year	(255)
Balance as at 31 December 2020	2,123
Balance as at 1 January 2019	2,254
Movement in impairment allowance	(182)
Amounts utilised during the year	5
Balance as at 31 December 2019	2,077

Based on past experience, the Scheme believes that no provision for impairment is required in respect of Contribution debtors. For member and service provider claims debtors that are past due and outstanding for less than 90 days, past experience has indicated that no provision is required.

The Scheme applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for other receivables.

To measure the expected credit losses associated with other receivables, these have been grouped based on shared credit risk characteristics and the days past due. Other receivables comprise sundry accounts receivable and interest receivable and are all current and not in a past due status. No expected loss rate is assigned to receivables that are not past due. Any loss associated to these receivables is negligible and no provision is raised.

25. FINANCIAL RISK MANAGEMENT REPORT (continued)

Credit risk (continued)

Credit quality

The credit quality of financial assets that are neither past due nor impaired can be assessed by historical information about counterparty default rates:

	2020 R'000	2019 R'000
Insurance receivables		
Contributions receivable	4,381	3,362
Member and service provider claims receivable		
Active member claims receivable	118	95
Withdrawn member claims receivable	25	31
Service provider claims receivable	528	578
Forensic receivables	364	380
	5,416	4,446

Contribution receivables

The Scheme collected over 99% (2019: 99%) of outstanding debt in January 2021. Therefore we can reasonably conclude that the credit quality of contribution debtors is high. Consequently no additional disclosure of the credit quality is provided.

Active member claim receivables

These debtors are active members of the Scheme. No further provision for impairment is therefore necessary.

Withdrawn member claim receivables

These amounts are due from members that have withdrawn from the Scheme. An impairment allowance covering 86% (2019: 91%) of the total amount due has been raised and the Trustees are satisfied that this is adequate.

Service provider claim receivables

These debtors are the healthcare providers of the Scheme. The amounts due to the Scheme are offset against future payments to be made to these providers. An impairment allowance covering 79% (2019: 75%) of the total amount due has been raised and the Trustees are satisfied that this is adequate.

Cash and cash equivalents

	2020 R'000	2019 R'000
Invested with counterparties with high quality credit ratings	229,465	247,895

25. FINANCIAL RISK MANAGEMENT REPORT (continued)

Unconsolidated investment structures

The asset managers invest the Scheme's monies in reputable funds which generate returns for the Scheme. The Scheme views these funds as unconsolidated structured entities. The Scheme monitors the performance of the funds closely to ensure the Scheme earns high returns without unnecessary exposure to risk. The Scheme does not control these funds as it has no voting rights, is not able to call meetings and in addition, has no ability to direct the relevant activities of these funds. As the Scheme does not control these funds, its investments in these structured entities are not consolidated in the Scheme's financial statements.

The Scheme has investments in certain pooled portfolios and collective investment schemes (the Funds) and exposure to these Funds as listed in the table below. The Scheme's maximum exposure is limited to the total fair value of its investments in the Funds.

Fund	As at 31 December 2020		As at 31 December 2019	
	Fair value of fund assets held R'000	% Fund exposure attributable to Scheme	Fair value of fund assets held R'000	% Fund exposure attributable to Scheme
Ninety One Money Market Fund Class Z	-	-	25	0.0%
Ninety One Ial Internal Bond	-	-	212	0.0%
Ninety One Ial Internal Money Upf Z	50,674	1.3%	140,344	2.6%
Ninety One Ial Stable Money Fund	442,778	29.2%	294,202	23.7%
Ninety One Stefi Plus Fund Z	10,482	0.1%	9,859	0.1%
Ninety One GSF US Dollar Money Fund	32,121	0.2%	64,034	0.3%
Ninety One GSF Global Franchise Fund	151,873	0.1%	-	-
Coronation Absolute Bond	151,009	3.1%	234,206	4.5%
ABAX SA Income Prescient Fund	20,440	8.3%	-	-
ABAX Global Equity Prescient Fund	4,930	0.4%	-	-
Nedgroup Corporate Money Market Fund	13,854	0.0%	-	-

Liquidity risk

Liquidity risk is the risk that the Scheme will not have sufficient liquid funds available to settle financial obligations as they fall due.

The Scheme's approach to managing liquidity is to ensure, with significant conservative margin, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Scheme's reputation. In order to meet the objectives of enhancing returns while also providing high liquidity, the combined Scheme portfolios have explicit constraints that guarantee liquidity of at least 20% of the Scheme assets within a period of one week.

The Scheme has complied with the requirements regarding the nature and categories of assets as prescribed by Section 35 and Regulation 30 of the Act.

Approximately 99% of the Scheme's insurance claim liabilities are settled within three months after the claim was incurred and the balance of the claims liability is settled within six months.

25. FINANCIAL RISK MANAGEMENT REPORT (continued)

Liquidity risk (continued)

An expected maturity analysis for financial liabilities, including insurance liabilities is provided below:

	Less than 1 month R'000	Between 2 and 4 months R'000	More than 4 months R'000	Total R'000
As at 31 December 2020				
Medical Savings Account liability	1,191	2,009	228,029	231,229
Trade and other payables	10,335	-	-	10,335
Outstanding risk claims provision	16,625	6,379	70	23,074
As at 31 December 2019				
Medical Savings Account liability	1,362	1,908	216,385	219,655
Trade and other payables	15,218	-	-	15,218
Outstanding risk claims provision	11,757	7,633	59	19,450

26. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The Scheme makes estimates and assumptions that affect the reported amounts of assets and liabilities within the next financial year. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Outstanding claims provision

The critical estimates and judgements relating to the outstanding claims provision are set out under Note 5.

Other risk transfer arrangements

The critical estimates and judgements relating to other risk transfer arrangements are set out under Note 10.

Impairment of assets

The critical estimates made by the Scheme are set out under Note 25 and judgements relating to the impairment of assets are set out under Note 2.

27. NON-COMPLIANCE WITH THE MEDICAL SCHEMES ACT

The Trustees are of the opinion that there are no material deviations from the Act as a result of the Scheme having obtained the necessary exemptions from the Council for Medical Schemes to achieve compliance.

27.1 Outstanding contributions**Nature and impact**

In terms of Section 26(7) of the Act, contributions should be received in accordance with the rules of the Scheme. Per the Scheme rules, contributions are required to be received within three days after their due date. Instances were noted where contributions were received late.

Causes for failure

Balances after three days are due to reconciling discrepancies between the participating employers and the Scheme. The risk of default on payments due to the Scheme is small because of the restricted nature of the Scheme and employer base. The Trustees consider this to be immaterial.

Corrective action

Suspension policies are in place and applied where contributions are outstanding for individual paying members outside the participating employers' obligation.

27.2 Investment in participating employer**Nature and impact**

Section 35(8)(a) of the Act states that a medical scheme shall not invest any of its assets in a participating employer. During the year the Scheme had exposure to investments in participating employer groups through pooled investment vehicles.

Causes for failure

The Scheme invests in pooled investment vehicles which allow investment managers discretion to invest in a combination of shares and bonds that will best achieve their stipulated benchmark. Given this approach, the Scheme was exposed to participating employer shares.

Corrective action

The Scheme applies annually to the Council for Medical Schemes and received an exemption from this section of the Act. This exemption is valid until 30 November 2022.

27. NON-COMPLIANCE WITH THE MEDICAL SCHEMES ACT (continued)

27.3 Investment in administrator

Nature and impact

Section 35(8)(c) of the Act states that a medical scheme shall not invest any of its assets in any administrator. During the year the Scheme had exposure to such investments through pooled investment vehicles.

Causes for failure

The Scheme invests in pooled investment vehicles which allow investment managers discretion to invest in a combination of shares and bonds that will best achieve their stipulated benchmark.

Corrective action

The Scheme applies annually to the Council for Medical Schemes and received an exemption from this section of the Act. This exemption is valid until 30 November 2022.

27.4 Sustainability of benefit options

Nature and impact

In terms of section 33(2) of the Act, each benefit option shall be self-supporting in terms of membership and financial performance. At 31 December 2020, the Managed Care plan incurred deficits before investment income as set out in Note 23 to the financial statements.

Causes for failure

The Board of Trustees annually maintain market related benefit offerings and competitive contribution increases. Due to the Scheme demographics, this gives rise to the non-compliance.

Corrective action

Anglo American South Africa sold numerous subsidiaries over a period of time resulting in the loss of active employees and retention of pensioners. To compensate the Scheme for the resultant high pensioner ratio and expected deterioration of the claiming profile, the participating employers pre-funded the additional liability to the extent that the Scheme could maintain market related benefits and contribution increases into the future. The Scheme meets its responsibility to the members by subsidising the expected claims excess over contributions from the reserves. The Trustees will continue to review the investment returns to align with the strategy ensuring sustainability.

The Council for Medical Schemes is aware of the Scheme's strategy and approves the benefits and contributions annually without any requirement to take further corrective action.

27. NON-COMPLIANCE WITH THE MEDICAL SCHEMES ACT (continued)

27.5 Payment of claims within 30 days

Nature and impact

In terms of section 59(2) of the Act a member or provider claim should be settled within 30 days of submission. Instances were noted where settlements took more than 30 days.

Causes for failure

Delays can occur when accounts are referred for clinical audit or other investigations. These are however exceptions and claims are generally paid within the prescribed time.

Corrective action

The Scheme is aware of the requirements and complies as far as possible. It is however an inherent part of the industry that a limited number of problematic claims may exceed the payment requirement of 30 days.

27.6 Prescribed minimum benefits

Nature and impact

Section 29(1)(o) and Regulation 8 provide the scope and level of minimum benefits that the Scheme must provide to members and dependants.

Causes for failure

During the year under review there were isolated instances where the Scheme did not pay claims in accordance with the scope and level of minimum benefits.

Corrective action

The Scheme has aligned its interpretation of prescribed minimum benefits with CMS's interpretation, and affected claims are being reprocessed to ensure correct payment.